

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

The effect of adding chocolate with a high percentage of cocoa and polyphenols to a normal diet on blood pressure, vascular function, body composition, quality of life and cognitive performance in postmenopausal women. Randomized clinical trial. ECCAMP Study.

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-024095
Article Type:	Protocol
Date Submitted by the Author:	09-May-2018
Complete List of Authors:	Garcia-Yu, Irene; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); Consejería de Sanidad, Junta de Castilla y León, Public Health Information Garcia-Ortiz, Luis; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Department of Biomedical and Diagnostic Sciences Gomez-Marcos, Manuel; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Medicine Alonso-Dominguez, Rosario; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL) González-Sánchez, J; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); González-Sánchez, J; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Extremadura, Nursing Mora-Simon, Sara; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Basic Psychology, Psychobiology and Behavioral Sciences Methodology González-Manzano, Susana; University of Salamanca, Analytical Chemistry Rodriguez-Sanchez, Emiliano; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); Recio-Rodriguez, Jose; Institute of Biomedical Resea

Keywords:	chocolate, postmenopause, arterial pressure, vascular stiffness, body composition, quality of life
	SCHOLAR ONE [™]
	Manuscripts

Page 2 of 29

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

2	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
 11 12 13 14 15 16 17 18 19 20 21 	
19	
20 21	
21 22 23 24 25 26	
22	
23	
25	
26	
27	
28	
29	
30	
31	
31 32 33 34 35 36	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42 43	
43 44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1 2

1 TITLE: The effect of adding chocolate with a high percentage of cocoa and 2 polyphenols to a normal diet on blood pressure, vascular function, body 3 composition, quality of life and cognitive performance in postmenopausal 4 women. Randomized clinical trial. ECCAMP Study.

5

6

AUTHORS:

Irene A Garcia-Yu^{1,2}, Luis Garcia-Ortiz^{1,3}, Manuel A Gómez-Marcos^{1,4}, Rosario AlonsoDominguez¹, Jesus Gonzalez-Sanchez^{1,5}, Sara Mora-Simon^{1,6}, Susana GonzálezManzano⁷, Emiliano Rodriguez-Sanchez^{1,4}, Jose A Maderuelo-Fernandez^{1*}, Jose I
Recio-Rodriguez^{1,8*}

Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care
 Research Unit, La Alamedilla Health Center. Health Service of Castilla y León
 (SACyL), Salamanca, Spain.

Public Health Information Service, Consejería de Sanidad, Junta de Castilla y León,
 Valladolid, Spain.

16 3. Department of Biomedical and Diagnostic Sciences, University of Salamanca,

17 Salamanca, Spain.

18 4. Department of Medicine, University of Salamanca, Salamanca, Spain.

19 5. Department of Nursing, University of Extremadura, Plasencia, Spain.

20 6. Department of Basic Psychology, Psychobiology and Behavioral Sciences

- 21 Methodology, University of Salamanca, Salamanca, Spain.
- 22 7. Department of Analytical Chemistry, University of Salamanca, Salamanca, Spain.
- 8. Department of Nursing and Physiotherapy, University of Salamanca, Salamanca,
- 24 Spain.
- ²⁵ *These authors contributed equally to this work.
- 26 **CORRESPONDING AUTHOR:**

27 Irene A Garcia-Yu

28 Primary Care Research Unit, The Alamedilla Health Centre. 37003 Salamanca, Spain.

BMJ Open	ш
	BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.
ireneailinggarciayu@gmail.com	en: fir:
0034923231859	st pub
	lished
	l as 10 F
	.1136/ ⁹ rotec1
	bmjop .ed by
	en-201 copyri
	8-024(ght, in
)95 on Icludin
	14 De g for u
	cembe Ensei(Ises re
	r 2018. Jneme lated t
	, Down nt Sup o text
	iloader erieur and da
	d from (ABES Ita min
	http:// s) . iing, A
	bmjop I traini
	<mark>en.bm</mark> ng, an
	j.com/ d simil
	on Ju lar tecl
	ne 7, 2 hnolog
	025 at jies.
	Agenc
	e Bibl
	liograp
2	shique
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	de I

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

31 ABSTRACT

Introduction: The intake of polyphenols has shown certain health benefits. The aim of this study is to assess the effect of adding a daily amount of chocolate high in cocoa content and polyphenols to the normal diet on blood pressure, vascular function, cognitive performance, quality of life and body composition in postmenopausal women. Methods and analysis: Randomized clinical trial with two parallel groups involving a total of 140 women between 50 and 64 years of age in the postmenopausal period, defined by amenorrhea of at least 12 consecutive months. The main variable will be the change in blood pressure. Secondary variables will be changes in vascular function, quality of life, cognitive performance and body composition. The intervention group will be given chocolate containing 99% cocoa, with instructions to add 10 g daily to their normal diet for 6 months. The daily nutritional contribution of this amount of chocolate is 59 Kcal and 65.4 mg of polyphenols. There will be no intervention in the control group. All variables will be measured at the baseline visit and at 3 and 6 months after randomization, except cognitive performance and quality of life, to be assessed only at baseline and at 6 months. Recruitment is scheduled to begin on June 1, 2018, and the study will continue until May 31, 2019.

Ethics and dissemination: This study was approved by the Clinical Research Ethics 49 Committee of the Health Area of Salamanca, Spain ("CREC of Health Area of 50 Salamanca") in February 2018. A SPIRIT checklist is available for this protocol. The 51 clinical trial has been registered at ClinicalTrials.gov provided by the US National 52 Library of Medicine, number NCT03492983.

Keywords: Chocolate, postmenopause, arterial pressure, vascular stiffness, body
 composition, quality of life.

Strengths and limitations of this study:

The effect of commercially available chocolate high in cocoa and polyphenols on the health of postmenopausal women is not known since most of the available studies have used laboratory compounds prepared with high composition of these substances.

Blood pressure and vascular function will be measured objectively using a sphygmomanometer and a Vasera VS-2000 device (Fukuda Denshi), with body composition measured by impedance analysis, while quality of life and cognitive performance will be assessed using validated instruments.

Due to the nature of the intervention, the participants cannot be blinded, although the researchers who perform the measurements and the statistical analysis will be

blinded.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

69 INTRODUCTION

Polyphenols are bioactive compounds found in many plants, fruits and vegetables. The beneficial effects on human health associated with the consumption of a diet rich in polyphenols has generated great scientific interest in these substances ¹⁻³. The action of polyphenols is based on their antioxidant capacity through the uptake of free radicals, the chelation of metals with redox properties and the modulation and inhibition of enzymatic activity ⁴.

The most abundant polyphenols in cocoa are flavonoids, which have been linked to a protective effect against cardiovascular disease, decreasing the risk of cardiovascular morbidity and mortality, and favouring the prevention of other chronic diseases such as diabetes mellitus type 2 ^{1-3 5 6}. The ability to reduce cardiovascular risk could be due to an improvement in the elements that define metabolic syndrome, the improvement of vascular endothelial dysfunction, insulin resistance and the inhibition of platelet activation and aggregation ^{7 8}.

Cocoa polyphenols and blood pressure: The effect of consuming polyphenols present in chocolate on the blood pressure (BP) statistics of healthy individuals is not clear. Some studies have observed a dose-dependent relationship between cocoa intake and clinical BP, with higher consumption equated to lower blood pressure and better vascular function ⁹ ¹⁰. Conversely, other research has not obtained significant changes in these parameters related to the supplementation of cocoa or pure polyphenols such as epicatechin or quercetin ¹¹ ¹².

90 Endothelial dysfunction in postmenopausal women causes changes that favour the 91 development of cardiovascular risk factors and atherosclerosis, which lead to the 92 appearance and maintenance of hypertension ¹³ ¹⁴. A decrease in BP has been 93 observed in this group after daily consumption of cocoa with a flavonol content of 40.12 94 mg. Below this level, however, no changes have been observed ¹⁵.

95 Cocoa polyphenols and vascular function: Among healthy individuals as well as
 96 postmenopausal women, the consumption of polyphenols present in cocoa has been

97 associated with a dose-dependent improvement of vascular function, in particular of
98 arterial stiffness measured by pulse wave speed ^{9 10 15}. However, this relationship is not
99 evident in people with mild hypertension when cardio-ankle vascular index (CAVI) is
100 used as a measure of arterial stiffness ¹⁶.

101 There is also evidence of the influence of these polyphenols in reducing the 102 augmentation index (Alx). The study by West et al ¹⁷, involving subjects with excess 103 weight and moderate obesity, concludes that the treatment with dark chocolate 104 decreases Alx in women, although it seems that this association may affect more the 105 elasticity of the large arteries, especially in subjects with obesity and diabetes mellitus 106 type 2 ¹⁸.

Cocoa polyphenols and cognitive performance: There is evidence to suggest that chocolate rich in polyphenols may be beneficial for cognitive performance and state since it improves mental processing speed and attenuates the increase of mental fatigue among healthy young adults ^{19 20}. An improvement in cognitive performance among older age groups after eating chocolate has also been observed ²¹. Several studies also show that polyphenol-rich chocolate causes an improvement in executive function and categorical fluency²², in working memory^{23 24}, and a slowing of mental fatigue ²⁵. Furthermore, a positive influence of cocoa polyphenols on physiological processes has been reported, with a neuroprotective effect ²⁶ and improved cognitive performance²⁷.

Cocoa polyphenols and quality of life: The quality of life linked to health is represented by the individual's perception of well-being in various aspects of life, including physical and mental aspects. The effect of chocolate and polyphenols on the quality of life has scarcely been studied, with not a great deal of evidence available and even less of a conclusive nature. In a study conducted among healthy people, where regular consumption of chocolate was recorded over a year, no evidence was found of a clear association between chocolate intake and the physical or mental components of BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Page 8 of 29

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

quality of life ²⁸. Nevertheless, it has been observed that the consumption of dark
chocolate may be beneficial for the quality of life of women with fibromyalgia ²⁹.

Cocoa polyphenols and body composition: The menopause period leads to various changes in the body composition of women ³⁰. Regarding the connection between cocoa polyphenols and body composition, results diverge. Some clinical trials involving healthy people and overweight or obese patients have not reported significant differences that link chocolate consumption to anthropometric measures ^{12 16 17 31}. Other studies indicate that chocolate consumption may have positive effects on body composition in adolescents ³², patients with diabetes ³³ or women with obesity ³⁴. Two recent systematic reviews also indicate that eating chocolate is associated with reduced body mass index (BMI) and waist circumference ^{35 36}, and one of them also concludes that the amount and the length of time during which it is eaten play a key role in these beneficial effects ³⁶. Conversely, other studies such as that carried out with the cohort of the Atherosclerosis Risk in Communities (ARIC) study have observed a dose-dependent increase in weight after habitual chocolate consumption ³⁷.

In sum, the polyphenols present in chocolate seem to have a positive effect on BP, vascular function, cognitive performance and quality of life, especially in populations with increased cardiovascular risk such as postmenopausal women ³⁸. However, the conflicting results obtained in different studies suggest that the real contribution of these compounds to health and the underlying mechanisms remain unclear. Moreover, most of these studies have used preparations with high concentrations of polyphenols that are usually not present in the normal diet.

This study aims to evaluate the effect of adding a daily amount of 10 g of chocolate high in cocoa content (99%) and polyphenols to the normal diet on blood pressure, vascular function, cognitive performance, quality of life and body composition in postmenopausal women.

150 METHODS AND ANALYSIS

Design and setting:

This controlled and randomized clinical trial involves two parallel groups. The study will be carried out in the Research Unit of the La Alamedilla Health Centre in Salamanca (Spain), which is part of the Biomedical Research Institute of Salamanca (IBSAL) and the Primary Care Prevention and Health Promotion Research Network (REDIAPP). The recruitment schedule is set to start on June 1, 2018, and the study will run until May 31, 2019. There will be a baseline assessment and two follow-ups, at 3 and 6 months.

Study population:

160 Those subjects who meet the selection criteria and sign the informed consent after 161 receiving information about the objectives and implementation of the study will take 162 part.

163 Inclusion criteria: women between 50 and 64 years of age in postmenopause, defined
164 by and checked against amenorrhea during at least 12 consecutive months.

Exclusion criteria: personal history of cardiovascular disease; personal history of diabetes mellitus, arterial hypertension or dyslipidemia under pharmacological treatment: hypocaloric diets: clinically demonstrable neurological and/or neuropsychological disease; treatment with hormone replacement therapy; intolerance and/or allergy to cocoa or any of the components of the supplement.

Participants will be selected using a consecutive sample of women who meet the
selection criteria in the GP surgeries of four urban primary care centres in Salamanca,
from June 1, 2018.

173 Sample size:

The size of the sample has been estimated based on the potential modification of the main variable, systolic blood pressure (SBP). Given alpha and beta risks of 0.05 and 0.20 respectively in bilateral contrast and a standard deviation (SD) of 5.8 mmHg, 140 participants (70 per group) will be necessary to detect a minimum difference of 2.9 mmHg in the SBP between the two groups. A predicted drop-out rate of 10% during follow-up has been taken into account. This estimate has considered the results 180 obtained in a similar study in which a decrease in SBP of 6.5 was observed \pm 5.8 181 mmHg ¹⁰.

182 Randomization:

Participants will be assigned to the intervention group (IG) or control group (CG) at random. The allocation sequence will be generated by an independent researcher using the Epidat 4.2 program ³⁹ and will remain hidden until the participants are assigned to each group.

187 Intervention:

188 No type of intervention will be carried out with the CG participants.

189 IG participants will be given chocolate with 99% cocoa content and asked to eat 10 g 190 daily for a period of 6 months. Participants will also be given instructions on eating and 191 keeping the product, with the recommendation, for example, that the daily chocolate 192 intake be eaten at the same time. In addition, they will be given a calendar on which to 193 record the time it was eaten each day. This calendar will be returned to the researchers 194 at each replenishment visit.

This amount of chocolate provides the following daily nutritional contribution: 59 Kcal, 0.8 g of carbohydrates, 1.5 g of protein, 5.1 g of fat, of which 3.1 g are saturated fats. The proportion of polyphenols per 10 g is 65.4 mg. The polyphenolic profile of this compound can be seen in table 1. On each visit, IG participants will receive the amount of chocolate they need until the next replenishment visit. In addition to the baseline visit, there will be 5 replenishment visits in months 1, 2, 3 (coinciding with the evaluation visit), 4 and 5. The sole purpose of the replenishment visits will be to supply the amount of chocolate needed until the next visit, without any other intervention being carried out.

Participants in both groups will be instructed to continue with the dietary pattern they
usually follow, without changing their eating habits during the study period.

Procedures:

BMJ Open

For each participant a baseline visit and two follow-up visits at 3 and 6 months after the initial one are scheduled (Figure 1). The IG will also make 5 replenishment visits, in months 1, 2, 3 (coinciding with the first follow-up visit), 4 and 5. In the replenishment visits they will be given the amount of chocolate needed until the next visit and will hand in the calendar with the record of the chocolate eaten.

Primary and secondary endpoints:

The primary variable will be the decrease in clinical BP, measured with a digital sphygmomanometer. Secondary variables will include vascular function, quality of life, cognitive performance and body composition.

All variables will be measured at 3 and 6 months after randomization, except for cognitive performance and quality of life, to be assessed only after 6 months.

218 Blood pressure:

Clinical systolic and diastolic blood pressure will be measured with a validated Omron
M10-IT sphygmomanometer (Omron Healthcare, Kyoto, Japan). Three measurements
will be taken in the dominant arm of the subject in a sitting position after at least 5
minutes of rest with an appropriately sized cuff, following the recommendations of the
European Society of Hypertension ⁴⁰. The average of the last two measurements will
be recorded.

225 Vascular function:

The Vasera VS-2000 device (Fukuda Denshi) will be used to measure the CAVI and the brachial-ankle pulse wave velocity (ba-PWV) at rest. CAVI is a good indicator of arterial stiffness, providing an accurate estimate of the degree of atherosclerosis without depending on blood pressure ⁴¹. CAVI \geq 9 and ba-PWV \geq 18.3 will be considered pathological ⁴². Pathological CAVI is representative of subclinical atherosclerosis ⁴³.

232 Cognitive performance:

Attention and executive functions: Trail Making Test A will be used to measure
 attention and Trail Making Test B for processing speed and executive functions ⁴⁴.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Immediate verbal memory will be assessed with the Rey Auditory Verbal Learning
Test. The immediate recall of a list of 15 words is measured in three attempts, followed
by delayed verbal memory through the free recall of the words learned in the first part
of the test after 10 minutes ⁴⁵.

239 Working memory will be assessed with the WAIS Digit Span Backward test ⁴⁶.

240 Phonological fluency will be explored by naming as many words as possible starting

241 with different letters of the FAS Questionnaire in the space of one minute ⁴⁷.

242 Categorical fluency measures verbal semantic fluency and will be assessed by naming

243 as many animals as possible in one minute 48 .

244 Quality of life:

The quality of life linked to health will be assessed through the EuroQol 5-D questionnaire (EQ-5D). We will use the adapted Spanish version of this questionnaire, which has been validated in the Spanish population ⁴⁹. This guestionnaire consists of three elements: the assessment by the individuals of their state of health in level of severity by dimension (mobility, personal care, daily activities, pain/discomfort and anxiety/depression), the assessment of their state of health on an analogue visual scale, and finally an index of social values obtained for each state of health generated by the instrument.

The quality of life will also be studied using the Cervantes Scale ⁵⁰. This questionnaire is specifically designed for menopause and postmenopause and has been validated for Spanish women. Its 31 structured items cover the 4 dimensions of menopause: menopause and health, sexuality, psychic domain and relationships.

Body composition:

Body composition will be measured with the Inbody 230 Monitor ⁵¹. This analyzer
provides data on skeletal muscle mass, fat mass, total body water, fat-free mass,
percentage of body fat, waist-hip ratio, basal metabolism, and also a segmental
analysis.

BMJ Open

Body weight will be measured twice with an electronic scale (Scale 7830, Soehnle Professional GmbH & Co, Backnang, Germany) after proper calibration (accuracy ± 0.1 kg). Height will be measured by recording the average of two readings rounded to the nearest centimetre using a stadiometer (Seca 222, Medical scale and measurement system, Birmingham, UK). Both measurements will be made with the subject barefoot and wearing light clothing. Body mass index will be calculated by dividing weight (kg) by height squared (m²). Waist circumference will be assessed in accordance with the recommendations of the Spanish Society for the Study of Obesity (SEEDO) ⁵² and will be measured in duplicate before and after inhalation, using a flexible tape parallel to the floor, at the level of the mid-point between the lowest rib and the iliac crest, with the subject standing up and without clothes.

- 273 Other variables
- 274 Clinical and sociodemographic variables

At the baseline visit, information on clinical and sociodemographic variables will also be collected via questions about age, marital status, educational level and occupation. Family history of cardiovascular disease and personal history of anxiety and/or depression, gestational diabetes, hypertension, dyslipidemia and the prescribed pharmacological treatment (antiaggregants, anticoagulants, thyroid hormone treatment, anxiolytics) will also be recorded, as well as the taking of NSAIDs in the last two weeks. In subsequent visits, personal histories of cardiovascular disease, diabetes mellitus, arterial hypertension or dyslipidemia in treatment, as well as the prescribed pharmacological treatment (hypolipidemic, antihypertensive, antidiabetic) will also be noted.

285 Evaluation of chocolate consumption and habitual diet

Chocolate consumption will be assessed at each evaluation visit by a series of
questions about the amount, type and frequency of consumption in the period between
visits.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

289 Nutritional habits will be assessed by a 24-hour log on 3 non-consecutive days prior to

each visit.

291 Evaluation of other lifestyles

The use of tobacco will be assessed with a questionnaire on the personal history and pattern of smoking.

Alcohol use will be recorded with a questionnaire covering the previous 7 days which will include specific beverages and the amount by volume drunk of each.

Physical activity will be measured using the International Physical Activity Questionnaire (IPAQ) in its short version and validated in Spanish ⁵³. This questionnaire measures activity over the previous 7 days, classifying the subjects according to three activity levels (low, moderate and high) with respect to three types of activities: walking, moderate-intensity activities and vigorous-intensity activities. The amount of physical exercise will be estimated in METs-minute/week.

302 Evalua

Evaluation of laboratory variables

At baseline and follow-up visits at 6 months, we will measure plasma fasting glucose values (mg/dL), glycated haemoglobin (%), total cholesterol (mg/dL), total triglycerides (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), creatinine (mg/L), insulinemia (mg/dL). Creatinine in urine (mg/dL) and microalbuminuria (mg/dL) will also be measured.

Insulin resistance will be determined using the HOMA index (Homeostasis Model
Assessment Insulin Resistance) estimated using the following equation: Fasting
glucose (mmol/l) X insulin (mU/ml)/22.5.

311 Blinding strategy:

Due to the nature of the intervention itself, the participants and the person responsible for delivering the chocolate to IG participants, cannot be blinded. However, the person responsible for carrying out the study measurements at each visit and for the statistical analysis will be blind to the intervention.

1 2	
3	
4	
5	
6	
7 8	
o 9	
10	
11	
12	
13	
14 15	
16	
16 17	
18	
19 20	
21	
22	
23	
24	
25 26	
27	
28	
29	
30 31	
32	
33	
34	
35 36	
30 37	
38	
39	
40	
41 42	
43	
44	
45	
46 47	
47 48	
49	
50	
51	
52 53	
55 54	
55	
56	
57	
58 59	
60	

316 Statistical analysis:

317 General analysis

318 Results for the quantitative variables will be expressed by mean ± standard deviation or by frequency distribution in the case of qualitative ones. The normality of the variables 319 320 will be assessed using the Kolmogorov-Smirnov test. In cases where a normal 321 distribution cannot be assumed, the corresponding nonparametric tests will be applied. 322 The association between independent qualitative variables will be analyzed by means 323 of the chi-square test or Fisher's exact test. The means between the two groups will be 324 compared using the Student's t test or the Mann-Whitney U test, and the Pearson or 325 Spearman correlation coefficients will be calculated to analyze the relationship between 326 quantitative variables.

The analysis of the results for the main variable and the secondary variables will be carried out by intention to treat. In addition, a secondary analysis will be run taking into account chocolate intake adherence (< 50% days and > 50% days) and other relevant subgroups in relation to their physical activity or previous chocolate consumption.

331 All analyses will be performed with the SPSS version 23.0 (IBM Corporation, Armonk,

332 NY, USA) and an alpha risk of 0.05 will be set as the limit of statistical significance.

333 Analysis of the intervention's effect on primary and secondary outcomes.

To analyze the changes at 3 and 6 months from baseline in the primary outcome (blood pressure) and in the secondary outcomes within the same group, the Student's t test for paired data or the Wilcoxon test will be used. The McNemar test will be applied with quantitative or dichotomous variables.

Effects of the intervention will be analyzed in a comparison of the changes in blood pressure and the secondary variables between the IG and the CG, using ANCOVA and adjusting for possible confounders. Effects of the intervention during follow-up will be studied with an analysis of the variance of repeated measures.

342 Analysis by subgroups.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Page 16 of 29

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The effect of the intervention could be influenced by age, sociocultural level and adherence to the study's chocolate intake. The same analyses described above will be performed for each of the aforementioned subgroups.

346 Secondary analyses.

A multivariate multiple regression analysis will be performed to identify the variables
with the greatest influence on blood pressure changes and the secondary variables
analyzed.

350 Methodological limitations:

Due to the nature of the intervention, the participating subjects cannot be blinded. However, the researcher who analyses the data and the person who makes the measurements during follow-up visits will be blinded with respect to the group to which the participants belong.

Assessment of the quality of life and lifestyles will be carried out through self-reported data; however, previously validated instruments will be used to obtain these. To make compliance with the intervention in the IG easier, IG participants will be provided with instructions on eating the chocolate and a calendar to record each intake.

359 ETHICS AND DISSEMINATION

360 Ethical considerations:

The study was approved by the Clinical Research Ethics Committee of the Salamanca Health Area ("CREC of Health Area of Salamanca") in February 2018. A SPIRIT checklist is available for this protocol. The clinical trial has been registered at ClinicalTrials.gov with the identifier NCT03492983.

365 Participants must sign informed consent in accordance with the Declaration of Helsinki.
366 Subjects will be informed of the objectives of the project and the risks and benefits of

the explorations to be carried out, including sample collection. None of the tests will pose risks that could endanger the lives of participants. Confidentiality of participant data will be guaranteed at all times in accordance with the provisions of the Organic Page 17 of 29

BMJ Open

Law on the Protection of Personal Data (15/1999 of December 13, LOPD), and under

the conditions established by Law 14/2007 of biomedical research.

Dissemination plan:

The research group plans to achieve rapid and widespread dissemination of results to ensure maximum visibility of this study. To this end, the results of the study will be published in scientific journals with peer review. At least one publication of the main results and others with the secondary results are planned. This will be complemented by presentation of the results of the study at relevant scientific conferences and seminars of national and international scope. In addition, a doctoral thesis based on this project will be prepared. Appropriate dissemination will likewise be carried out through social networks and other media. Moreover, given the involvement of a commercial product, the transfer to clinical practice is expected to be very fast if the results are as expected.

DISCUSSION

In recent years, there has been an increase in attention to polyphenols and their beneficial effects on health, with numerous studies being carried out to assess this ^{15 17}. Similarly, the therapeutic use of these compounds has been suggested for certain diseases or population groups ^{29 54}. The menopause increases the risk of developing cardiovascular disease compared to the previous period ³⁸. However, we have not found any study that assesses the effect of adding commercially available chocolate high in cocoa content to the usual diet in this population at special risk. Similarly, no studies have been found that evaluate the effects on cognitive performance, quality of life and body composition of adding commercial chocolate with high cocoa content to the usual diet in postmenopausal women.

The results of this work will provide new evidence in this regard for the development of strategies in nutritional education of particularly vulnerable populations, given their high risk of developing cardiovascular disease, including non-pharmacological therapies and strategies that employ lifestyle modification. This intervention may also have BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and

1		
2	400	REFERENCES
3	400	REFERENCES
4 5	401	1. Grassi D, Desideri G, Ferri C. Flavonoids: antioxidants against atherosclerosis. Nutrients
5	401	2010;2(8):889-902. doi: 10.3390/nu2080889 [published Online First: 2010/08/01]
6 7	403	2. Grassi D, Desideri G, Croce G, et al. Flavonoids, vascular function and cardiovascular
8	404	protection. <i>Curr Pharm Des</i> 2009;15(10):1072-84. [published Online First: 2009/04/10]
9	405	3. Visioli F, Bernaert H, Corti R, et al. Chocolate, lifestyle, and health. <i>Crit Rev Food Sci Nutr</i>
9 10	405	2009;49(4):299-312. doi: 10.1080/10408390802066805 [published Online First:
11	407	2009/02/24]
12	407	4. Cos P, De Bruyne T, Hermans N, et al. Proanthocyanidins in health care: current and new
13	408	trends. Curr Med Chem 2004;11(10):1345-59. [published Online First: 2004/05/12]
14	409	5. Grassi D, Desideri G, Ferri C. Blood pressure and cardiovascular risk: what about cocoa and
15	410	chocolate? Arch Biochem Biophys 2010;501(1):112-5. doi: 10.1016/j.abb.2010.05.020
16	411 412	[published Online First: 2010/05/25]
17	412	6. Ramos S, Martin MA, Goya L. Effects of Cocoa Antioxidants in Type 2 Diabetes Mellitus.
18	413	Antioxidants (Basel) 2017;6(4) doi: 10.3390/antiox6040084 [published Online First:
19	414 415	
20		2017/11/01]
21	416	7. Osakabe N. Flavan 3-ols improve metabolic syndrome risk factors: evidence and
22	417	mechanisms. J Clin Biochem Nutr 2013;52(3):186-92. doi: 10.3164/jcbn.12-130
23	418	[published Online First: 2013/05/25]
24	419	8. Engler MB, Engler MM, Chen CY, et al. Flavonoid-rich dark chocolate improves endothelial
25	420	function and increases plasma epicatechin concentrations in healthy adults. J Am Coll
26	421	Nutr 2004;23(3):197-204. [published Online First: 2004/06/11]
27	422	9. Heiss C, Sansone R, Karimi H, et al. Impact of cocoa flavanol intake on age-dependent
28	423	vascular stiffness in healthy men: a randomized, controlled, double-masked trial. Age
29	424	(Dordr) 2015;37(3):9794. doi: 10.1007/s11357-015-9794-9 [published Online First:
30	425	2015/05/28]
31	426	10. Grassi D, Desideri G, Necozione S, et al. Cocoa consumption dose-dependently improves
32 33	427	flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy
33	428	individuals. J Hypertens 2015;33(2):294-303. doi: 10.1097/hjh.000000000000412
35	429	[published Online First: 2014/11/08]
36	430	11. Crews WD, Jr., Harrison DW, Wright JW. A double-blind, placebo-controlled, randomized
37	431	trial of the effects of dark chocolate and cocoa on variables associated with
38	432	neuropsychological functioning and cardiovascular health: clinical findings from a
39	433	sample of healthy, cognitively intact older adults. Am J Clin Nutr 2008;87(4):872-80.
40	434	[published Online First: 2008/04/11]
41	435	12. Dower JI, Geleijnse JM, Gijsbers L, et al. Effects of the pure flavonoids epicatechin and
42	436	quercetin on vascular function and cardiometabolic health: a randomized, double-
43	437	blind, placebo-controlled, crossover trial. Am J Clin Nutr 2015;101(5):914-21. doi:
44	438	10.3945/ajcn.114.098590 [published Online First: 2015/05/03]
45	439	13. Modena MG. Hypertension in postmenopausal women: how to approach hypertension in
46	440	menopause. High Blood Press Cardiovasc Prev 2014;21(3):201-4. doi: 10.1007/s40292-
47	441	014-0057-0 [published Online First: 2014/05/24]
48	442	14. Zilberman JM, Cerezo GH, Del Sueldo M, et al. Association Between Hypertension,
49	443	Menopause, and Cognition in Women. J Clin Hypertens (Greenwich) 2015;17(12):970-
50	444	6. doi: 10.1111/jch.12643 [published Online First: 2015/08/08]
51	445	15. Okamoto T, Kobayashi R, Natsume M, et al. Habitual cocoa intake reduces arterial stiffness
52	446	in postmenopausal women regardless of intake frequency: a randomized parallel-
53 54	447	group study. Clin Interv Aging 2016;11:1645-52. doi: 10.2147/cia.s118152 [published
54 55	448	Online First: 2016/11/25]
55 56		
50 57		
58		
59		18
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

assi D, Desideri G, Ferri C. Flavonoids: antioxidants against atherosclerosis. Nutrients assi D, Desideri G, Croce G, et al. Flavonoids, vascular function and cardiovascular protection. *Curr Pharm Des* 2009;15(10):1072-84. [published Online First: 2009/04/10] ioli F, Bernaert H, Corti R, et al. Chocolate, lifestyle, and health. Crit Rev Food Sci Nutr 2009;49(4):299-312. doi: 10.1080/10408390802066805 [published Online First: s P, De Bruyne T, Hermans N, et al. Proanthocyanidins in health care: current and new assi D, Desideri G, Ferri C. Blood pressure and cardiovascular risk: what about cocoa and chocolate? Arch Biochem Biophys 2010;501(1):112-5. doi: 10.1016/j.abb.2010.05.020 mos S, Martin MA, Goya L. Effects of Cocoa Antioxidants in Type 2 Diabetes Mellitus. Antioxidants (Basel) 2017;6(4) doi: 10.3390/antiox6040084 [published Online First: sakabe N. Flavan 3-ols improve metabolic syndrome risk factors: evidence and mechanisms. J Clin Biochem Nutr 2013;52(3):186-92. doi: 10.3164/jcbn.12-130 gler MB, Engler MM, Chen CY, et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll iss C, Sansone R, Karimi H, et al. Impact of cocoa flavanol intake on age-dependent vascular stiffness in healthy men: a randomized, controlled, double-masked trial. Age (Dordr) 2015;37(3):9794. doi: 10.1007/s11357-015-9794-9 [published Online First: rassi D, Desideri G, Necozione S, et al. Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals. J Hypertens 2015;33(2):294-303. doi: 10.1097/hjh.000000000000412 rews WD, Jr., Harrison DW, Wright JW. A double-blind, placebo-controlled, randomized trial of the effects of dark chocolate and cocoa on variables associated with neuropsychological functioning and cardiovascular health: clinical findings from a sample of healthy, cognitively intact older adults. Am J Clin Nutr 2008;87(4):872-80.

449	16. Koli R, Kohler K, Tonteri E, et al. Dark chocolate and reduced snack consumption in mildly
450	hypertensive adults: an intervention study. Nutr J 2015;14:84. doi: 10.1186/s12937-
451	015-0075-3 [published Online First: 2015/08/25]
452	17. West SG, McIntyre MD, Piotrowski MJ, et al. Effects of dark chocolate and cocoa
453	consumption on endothelial function and arterial stiffness in overweight adults. Br J
454	Nutr 2014;111(4):653-61. doi: 10.1017/s0007114513002912 [published Online First:
455	2013/11/28]
456	18. Basu A, Betts NM, Leyva MJ, et al. Acute Cocoa Supplementation Increases Postprandial
457	HDL Cholesterol and Insulin in Obese Adults with Type 2 Diabetes after Consumption
458	of a High-Fat Breakfast. J Nutr 2015;145(10):2325-32. doi: 10.3945/jn.115.215772
459	[published Online First: 2015/09/05]
460	19. Scholey AB, French SJ, Morris PJ, et al. Consumption of cocoa flavanols results in acute
461	improvements in mood and cognitive performance during sustained mental effort. J
462	Psychopharmacol 2010;24(10):1505-14. doi: 10.1177/0269881109106923 [published
463	Online First: 2009/11/28]
464	20. Field DT, Williams CM, Butler LT. Consumption of cocoa flavanols results in an acute
465	improvement in visual and cognitive functions. Physiol Behav 2011;103(3-4):255-60.
466	doi: 10.1016/j.physbeh.2011.02.013 [published Online First: 2011/02/18]
467	21. Sorond FA, Hurwitz S, Salat DH, et al. Neurovascular coupling, cerebral white matter
468	integrity, and response to cocoa in older people. Neurology 2013;81(10):904-9. doi:
469	10.1212/WNL.0b013e3182a351aa [published Online First: 2013/08/09]
470	22. Mastroiacovo D, Kwik-Uribe C, Grassi D, et al. Cocoa flavanol consumption improves
471	cognitive function, blood pressure control, and metabolic profile in elderly subjects:
472	the Cocoa, Cognition, and Aging (CoCoA) Studya randomized controlled trial. Am J
473	Clin Nutr 2015;101(3):538-48. doi: 10.3945/ajcn.114.092189 [published Online First:
474	2015/03/04]
475	23. Grassi D, Socci V, Tempesta D, et al. Flavanol-rich chocolate acutely improves arterial
476	function and working memory performance counteracting the effects of sleep
477	deprivation in healthy individuals. J Hypertens 2016;34(7):1298-308. doi:
478	10.1097/hjh.0000000000000926 [published Online First: 2016/04/19]
479	24. Crichton GE, Elias MF, Alkerwi A. Chocolate intake is associated with better cognitive
480	function: The Maine-Syracuse Longitudinal Study. Appetite 2016;100:126-32. doi:
481	10.1016/j.appet.2016.02.010 [published Online First: 2016/02/14]
482	25. Massee LA, Ried K, Pase M, et al. The acute and sub-chronic effects of cocoa flavanols on
483	mood, cognitive and cardiovascular health in young healthy adults: a randomized,
484	controlled trial. Front Pharmacol 2015;6:93. doi: 10.3389/fphar.2015.00093 [published
485	Online First: 2015/06/05]
486	26. Nehlig A. The neuroprotective effects of cocoa flavanol and its influence on cognitive
487	performance. Br J Clin Pharmacol 2013;75(3):716-27. doi: 10.1111/j.1365-
488	2125.2012.04378.x [published Online First: 2012/07/11]
489	27. Nurk E, Refsum H, Drevon CA, et al. Intake of flavonoid-rich wine, tea, and chocolate by
490	elderly men and women is associated with better cognitive test performance. J Nutr
491	2009;139(1):120-7. doi: 10.3945/jn.108.095182 [published Online First: 2008/12/06]
492	28. Balboa-Castillo T, Lopez-Garcia E, Leon-Munoz LM, et al. Chocolate and health-related
493	quality of life: a prospective study. PLoS One 2015;10(4):e0123161. doi:
494	10.1371/journal.pone.0123161 [published Online First: 2015/04/23]
495	29. Costa de Miranda R, Paiva ES, Suter Correia Cadena SM, et al. Polyphenol-Rich Foods
496	Alleviate Pain and Ameliorate Quality of Life in Fibromyalgic Women. Int J Vitam Nutr
497	Res 2016:1-10. doi: 10.1024/0300-9831/a000253 [published Online First: 2016/11/22]
498	30. Dmitruk A, Czeczelewski J, Czeczelewska E, et al. Body composition and fatty tissue
499	distribution in women with various menstrual status. Rocz Panstw Zakl Hig
500	2018;69(1):95-101. [published Online First: 2018/03/10]
	19

1		
2	501	31. Davison K, Coates AM, Buckley JD, et al. Effect of cocoa flavanols and exercise on
3 4	501	cardiometabolic risk factors in overweight and obese subjects. Int J Obes (Lond)
5	503	2008;32(8):1289-96. doi: 10.1038/ijo.2008.66 [published Online First: 2008/05/28]
6	504	32. Cuenca-Garcia M, Ruiz JR, Ortega FB, et al. Association between chocolate consumption
7	505	and fatness in European adolescents. Nutrition 2014;30(2):236-9. doi:
8	506	10.1016/j.nut.2013.07.011 [published Online First: 2013/10/22]
9	507	33. Ayoobi N, Jafarirad S, Haghighizadeh MH, et al. Protective Effect of Dark Chocolate on
10	508	Cardiovascular Disease Factors and Body Composition in Type 2 Diabetes: A Parallel,
11	509	Randomized, Clinical Trial. Iran Red Crescent Med J 2017;19(8):e21644. doi:
12	510	10.5812/ircmj.21644 [published Online First: 2017-08-01]
13	511	34. Di Renzo L, Rizzo M, Sarlo F, et al. Effects of dark chocolate in a population of normal
14	512	weight obese women: a pilot study. Eur Rev Med Pharmacol Sci 2013;17(16):2257-66.
15	513	[published Online First: 2013/07/31]
16	514	35. González-Sarrías A, Combet E, Pinto P, et al. A Systematic Review and Meta-Analysis of the
17	515	Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition
18	516	and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy.
19 20	517	Nutrients 2017;9(7):746.
20 21	518	36. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate
21	519	supplementation have favorable effect on body weight, body mass index and waist
23	520	circumference? A systematic review, meta-analysis and dose-response of randomized
24	521	clinical trials. Crit Rev Food Sci Nutr 2018:0. doi: 10.1080/10408398.2018.1451820
25	522	[published Online First: 2018/03/20]
26	523	37. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a
27	524	dose-response manner. PLoS One 2013;8(8):e70271. doi:
28	525	10.1371/journal.pone.0070271 [published Online First: 2013/08/21]
29	526	38. Agrinier N, Cournot M, Dallongeville J, et al. Menopause and modifiable coronary heart
30	527	disease risk factors: a population based study. Maturitas 2010;65(3):237-43. doi:
31	528	10.1016/j.maturitas.2009.11.023 [published Online First: 2009/12/25]
32	529	39. Consellería de Sanidade Xunta de Galicia. Spain; Pan American Organization health (PAHO-
33	530	WHO); CES University C. Epidat: program for epidemiological data analysis. Version
34	531	4.2Julio 2016.
35	533	40, 2012 Departies suidelines for the monopowert of exterior humanian of the European
36 37	532	40. 2013 Practice guidelines for the management of arterial hypertension of the European
38	533	Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC
39	534	Task Force for the Management of Arterial Hypertension. J Hypertens
40	535	2013;31(10):1925-38. doi: 10.1097/HJH.0b013e328364ca4c [published Online First:
41	536	2013/10/11]
42	537	41. Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of
43	538 539	arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb
44	539 540	2011;18(11):924-38. [published Online First: 2011/06/02] 42. Ohkuma T, Tomiyama H, Ninomiya T, et al. Proposed Cutoff Value of Brachial-Ankle Pulse
45	540 541	Wave Velocity for the Management of Hypertension. <i>Circ J</i> 2017;81(10):1540-42. doi:
46	541 542	10.1253/circj.CJ-17-0636 [published Online First: 2017/08/25]
47	542 543	43. Korkmaz L, Erkan H, Korkmaz AA, et al. Relationship of aortic knob width with cardio-ankle
48	543 544	
49	544 545	vascular stiffness index and its value in diagnosis of subclinical atherosclerosis in
50	545 546	hypertensive patients: a study on diagnostic accuracy. <i>Anadolu Kardiyol Derg</i> 2012;12(2):102-6. doi: 10.5152/akd.2012.034 [published Online First: 2012/01/28]
51	540 547	44. Reitan RM. Trail Making Test. Tucson: Reitan Neuropsychology Laboratory 1992.
52	547	44. Reitan Riv. Train Making Test. Tucson. Reitan Neuropsychology Laboratory 1992. 45. Rey A. L'examen clinique en psychologie. Paris: Presses universitaires de France 1964.
53	549	46. Wechsler D. WMS-R Wechsler memory scale. San Antonio, Texas: The Psychological
54 55	550	Corporation 1987.
55 56	550	
57		
58		
59		20
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

47. Valencia NJ, Laserna, J. A., Pérez-García, M., Orozco, C., Miñán, M., Garrido, C., Morente, G.
Influencia de la escolaridad y el sexo sobre la ejecución en el FAS, nombrar animales y
nombrar frutas. *Psicología Conductual* 2000;8(2):283-95.

- 554 48. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986.
- 49. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan general
 population: feasibility and construct validity. *Qual Life Res* 1998;7(4):311-22.
 [published Online First: 1998/06/04]
- 55850. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish559women through and beyond menopause. Development and validation of the560Cervantes Scale]. Med Clin (Barc) 2004;122(6):205-11. [published Online First:5612004/03/12]
 - 56251. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable563bioelectrical impedance analyzer for the assessment of body composition. Appl Physiol564Nutr Metab 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First:5652013/02/02]
 - 566 52. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation of
 567 overweight and obesity and the establishment of therapeutic intervention criteria].
 568 *Med Clin (Barc)* 2007;128(5):184-96; quiz 1 p following 200. [published Online First:
 569 2007/02/15]
 - 570 53. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity
 571 questionnaire in the Catalan population (Spain)]. *Gac Sanit* 2013;27(3):254-7. doi:
 572 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30]
 - 573 54. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating
 574 Inflammation and Oxidation-Mediated Degenerative Diseases. Oxid Med Cell Longev
 575 2016;2016:5137431. doi: 10.1155/2016/5137431 [published Online First: 2016/10/11]

- 577 AUTHORS' CONTRIBUTIONS:
- 578 JIR, JAM, LGO and IGY contributed to the conception and design of the study. IGY,

579 JIR and JAM prepared the manuscript of the study protocol. JIR, JAM, LGO, RAD,

580 SMS, JGS, SMG, ERS, MGM and IGY contributed to the development of the study

- 581 protocol. JIR, JAM, LGO, RAD, SMS, JGS, SMG, ERS, MGM and IGY provided
- 582 assistance with statistical methodology and knowledge. JIR, JAM, LGO, RAD, SMS,
- 583 JGS, SMG, ERS, MGM and IGY provided a critical review of the manuscript.
- 584 All authors have read and accepted the final version of the protocol.
 - 585 FUNDING STATEMENT:
 - 586 This study was supported in part by grants funded by la Gerencia Regional de Castilla
 - 587 y León (GRS 1583/B/17).

Page 23 of 29

BMJ Open

*Lindt & Sprüngli will provide the necessary chocolate for the implementation of the
study. This company will not play any role in the design of the study, data analysis,
reporting of results, or the decision to present the manuscript for publication".

COMPETING INTERESTS STATEMENT:

592 The authors declare that they have no conflicts of interest.

593 ACKNOWLEDGMENTS:

594 The authors are grateful to all the professionals involved in the ECCAMP study:

José I Recio-Rodríguez, José A Maderuelo-Fernández, Luis García-Ortiz, Manuel A
Gómez-Marcos, Irene A García-Yu, Rosario Alonso-Domínguez, Sara Mora-Simón,
Natalia Sánchez-Aguadero, Jesús González-Sánchez, Cristina Agudo-Conde, Cristina
Lugones-Sánchez, Benigna Sánchez-Salgado, Carmen Castaño-Sánchez, Emiliano
Rodríguez-Sánchez, Susana González-Manzano, Olaya Tamayo-Morales, Susana
González-Sánchez.

FIGURE LEGEND:

602 Figure 1. Study flow chart

603 Table 1. Polyphenol composition of 99% cocoa chocolate

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)


tand

data mining, AI training, and similar technologies

Protected by copyright, including for uses related to text

Table 1. Polyphenols composition of 99% cocoa chocolate.





47

1

STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative	e informatior		
5 7 Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
3 9 Trial registratio	n 2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
)	2b	All items from the World Health Organization Trial Registration Data Set	3
Protocol versio	n 3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	21-22
6 Roles and	5a	Names, affiliations, and roles of protocol contributors	21
7 responsibilities	5b	Name and contact information for the trial sponsor	21-22
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	22
; ; ; ;	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	21
)			
<u>2</u> 3			1
2 5 6		Protected by copyright/ainglight/ainglight/sets/sepatient/comparison/or an endown of the set of th	

BMJ Open: first published as 10.1136/pmjopen-2018-024095 on 14 December 2018. Downloaded from http://pmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l

1 2					
3 4	Introduction				
5 6 7	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5-7	
8		6b	Explanation for choice of comparators	5-7	
9 10 11 12 13 14	Objectives	7	Specific objectives or hypotheses	7	
	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	8	
15 16	Methods: Participa	nts, inte	erventions, and outcomes		
17 18 19	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8	
20 21 22	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8	
23 24 25	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9	
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA	
		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	10	
		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	12	
	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-12	
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1	0
43					2
44 45		.6	Protected by copyrighty អាចប្រុស្តាទុក (ស្នាស្នាស្នាស្នាស្នាស្នាស្នាស្នាស្នាស្នា		
46 47	nce Bibliographique de	iəpA ts d	ed as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2029 Enseignement Superieur (SBBA) .	Open: first publish	BMJ

2 3 4	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8	
5 6 7	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8	
7 8 9	Methods: Assignm	ent of i	nterventions (for controlled trials)		
10	Allocation:				
11 12 13 14 15 16	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9	
17 18 19 20	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9	
21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9	
24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	13	
27 28 29 30		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	13	
31 32	Methods: Data coll	ection,	management, and analysis		
33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	10-12	
38 39 40		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	NA	
41 42 43					3
44			Protected by copyrighty and a set as the set and the set and the set and the set of the		
45 46 47	l əb əupidqraphique de l		ed as 10.5 ماريند. (md.nəqoįmd\/:ctth mont bəbsolnwol. 8102 vədməsəd 41 no 7004.8102-nəqoįmd\8511.01 ss bə (CBBA) . Brasingar 16 (CBBA) . Calana faringa far for for for for for for for for for fo	dəilduq tərif :nəc	BW1 OF

BMJ Open

2 3 4 5	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	NA				
6 7 8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	14				
9 10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14-15				
11 12 13 14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14-15				
15 16	Methods: Monitoring							
17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	NA				
22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA				
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	NA				
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA				
31 32	Ethics and dissemine	nation						
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	15				
37 38 39 40	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	15				
41 42 43				4				
44 45 46	əb əupirqpragoildi8 əɔn		ed as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 202 Enseigneent Superieur (ABES) . Protected by copyright,אַשָּפַוןקוּשָׁקָשָׁקָשָׁקָשָׁקָשָּלָפָאָשָלַקָּבָּאַפָּאַקָּאַפָּאַפּאַקָּקָבָּאַפּאַקק אַסָּלָפָאָשָאַשָּלַפָּאַפּאַפּאַפּאַפּאַפּאַפּאַפּאַפּאַפּאַפ	Asilduq triî :nəqO LMB				

2 3 4	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	15
5 6 7		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
8 9 10	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	15
1 2 3	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	22
4 5 6	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	NA
7 8 9	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	16
4 5		31b	Authorship eligibility guidelines and any intended use of professional writers	16
6 7 8		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	16
9)	Appendices			
2 2 3	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
 ;	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA
6 7 8 9 0	Amendments to the p	protocol	that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Construction should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Construction should be tracked and dated.	
1 2 3				Ę
44 45 46	ap ənbiydeısong əou		be 10/mojopen.bul oo \noo.imd.naqoimd\/.ctm dif add to make 2018. Downloaded to mttp://doi.oon.on.lone 7, 202 Enseignement Superieur (ABIA) . Protected by copyrightyingingingingingingingingingingingingingi	A Open: tirst publish

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://mgiopen.bmlone.com/ on June 7, 2025 at Agence Bibliographique de l

BMJ Open

Vascular and cognitive effects of chocolate with a high concentration of cocoa in postmenopausal women: a study protocol for a randomized clinical trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-024095.R1
Article Type:	Protocol
Date Submitted by the Author:	25-Jul-2018
Complete List of Authors:	Garcia-Yu, Irene; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); Consejería de Sanidad, Junta de Castilla y León, Public Health Information Garcia-Ortiz, Luis; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Department of Biomedical and Diagnostic Sciences Gomez-Marcos, Manuel; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Medicine Alonso-Dominguez, Rosario; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL) González-Sánchez, J; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL) González-Sánchez, J; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Extremadura, Nursing Mora-Simon, Sara; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Basic Psychology, Psychobiology and Behavioral Sciences Methodology González-Manzano, Susana; University of Salamanca, Analytical Chemistry Rodriguez-Sanchez, Emiliano; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL) Recio-Rodriguez, Jose; Institute of Biomedical Researc
Primary Subject	Nutrition and metabolism

Heading:	
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	chocolate, postmenopause, arterial pressure, vascular stiffness, body composition, quality of life
	SCHOLAR ONE [™]
	Manuscripts
	Manuscripts
Fag :=	only http://honionon.honi.com/site/shout/auidaline-subtral
For peer review	only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Note from the Editors: Instructions for reviewers of study protocols

Since launching in 2011, BMJ Open has published study protocols for planned or ongoing research studies. If data collection is complete, we will not consider the manuscript.

Publishing study protocols enables researchers and funding bodies to stay up to date in their fields by providing exposure to research activity that may not otherwise be widely publicised. This can help prevent unnecessary duplication of work and will hopefully enable collaboration. Publishing protocols in full also makes available more information than is currently required by trial registries and increases transparency, making it easier for others (editors, reviewers and readers) to see and understand any deviations from the protocol that occur during the conduct of the study.

The scientific integrity and the credibility of the study data depend substantially on the study design and methodology, which is why the study protocol requires a thorough peer-review.

BMJ Open will consider for publication protocols for any study design, including observational studies and systematic reviews.

Some things to keep in mind when reviewing the study protocol:

- Protocol papers should report planned or ongoing studies. The dates of the study should be included in the manuscript.
- Unfortunately we are unable to customize the reviewer report form for study protocols. As such, some of the items (i.e., those pertaining to results) on the form should be scored as Not Applicable (N/A).
- While some baseline data can be presented, there should be no results or conclusions present in the study protocol.
- For studies that are ongoing, it is generally the case that very few changes can be made to the methodology. As such, requests for revisions are generally clarifications for the rationale or details relating to the methods. If there is a major flaw in the study that would prevent a sound interpretation of the data, we would expect the study protocol to be rejected.

BMJ Open

1	TITLE: Vascular and cognitive effects of chocolate with a high concentration of
2	cocoa in postmenopausal women: a study protocol for a randomized clinical
3	trial.
4	AUTHORS:
5	Irene A Garcia-Yu ^{1,2} , Luis Garcia-Ortiz ^{1,3} , Manuel A Gómez-Marcos ^{1,4} , Rosario Alonso-
6	Dominguez ¹ , Jesus Gonzalez-Sanchez ^{1,5} , Sara Mora-Simon ^{1,6} , Susana González-
7	Manzano ⁷ , Emiliano Rodriguez-Sanchez ^{1,4} , Jose A Maderuelo-Fernandez ¹ *, Jose I
8	Recio-Rodriguez ^{1,8} *
9	1. Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care
10	Research Unit, La Alamedilla Health Center. Health Service of Castilla y León
11	(SACyL), Salamanca, Spain.
12	2. Public Health Information Service, Consejería de Sanidad, Junta de Castilla y León,
13	Valladolid, Spain.
14	3. Department of Biomedical and Diagnostic Sciences, University of Salamanca,
15	Salamanca, Spain.
16	4. Department of Medicine, University of Salamanca, Salamanca, Spain.
17	5. Department of Nursing, University of Extremadura, Plasencia, Spain.
18	6. Department of Basic Psychology, Psychobiology and Behavioral Sciences
19	Methodology, University of Salamanca, Salamanca, Spain.
20	7. Department of Analytical Chemistry, University of Salamanca, Salamanca, Spain.
21	8. Department of Nursing and Physiotherapy, University of Salamanca, Salamanca,
22	Spain.
23	*These authors contributed equally to this work.
24	CORRESPONDING AUTHOR:
25	Irene A Garcia-Yu
26	Primary Care Research Unit, The Alamedilla Health Centre. 37003 Salamanca, Spain.
27	ireneailinggarciayu@gmail.com
28	0034923231859
	1

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

ABSTRACT

Introduction: The intake of polyphenols has shown certain health benefits. The aim of this study is to assess the effect of adding a daily amount of chocolate high in cocoa content and polyphenols to the normal diet on blood pressure, vascular function, cognitive performance, quality of life and body composition in postmenopausal women. Methods and analysis: Randomized clinical trial with two parallel groups involving a total of 140 women between 50 and 64 years of age in the postmenopausal period, defined by amenorrhea of at least 12 consecutive months. The main variable will be the change in blood pressure. Secondary variables will be changes in vascular function, quality of life, cognitive performance and body composition. The intervention group will be given chocolate containing 99% cocoa, with instructions to add 10 g daily to their normal diet for 6 months. The daily nutritional contribution of this amount of chocolate is 59 Kcal and 65.4 mg of polyphenols. There will be no intervention in the control group. All variables will be measured at the baseline visit and at 3 and 6 months after randomization, except cognitive performance and quality of life, to be assessed only at baseline and at 6 months. Recruitment is scheduled to begin on June 1, 2018, and the study will continue until May 31, 2019.

Ethics and dissemination: This study was approved by the Clinical Research Ethics Committee of the Health Area of Salamanca, Spain ("CREC of Health Area of Salamanca") in February 2018. A SPIRIT checklist is available for this protocol. The clinical trial has been registered at ClinicalTrials.gov provided by the US National Library of Medicine, number NCT03492983. The results will be disseminated through open access peer-reviewed journals, conference presentations, broadcast media as well as presentation to stakeholders.

Keywords: Chocolate, postmenopause, arterial pressure, vascular stiffness, body composition, quality of life.

BMJ Open

57 Strengths and limitations of this study:

This study used a commercially available chocolate with high content of cocoa and
 polyphenols during the intervention.

Blood pressure and vascular function will be measured objectively using a
 sphygmomanometer and a Vasera VS-2000 device (Fukuda Denshi), with body
 composition measured by impedance analysis, while quality of life and cognitive
 performance will be assessed using validated instruments.

- Due to the nature of the intervention, the participants cannot be blinded, although
 the researchers who perform the measurements and the statistical analysis will be
- 66 blinded.

INTRODUCTION

Polyphenols are bioactive compounds found in many plants, fruits and vegetables. The beneficial effects on human health associated with the consumption of a diet rich in polyphenols has generated great scientific interest in these substances.[1-3] The action of polyphenols is based on their antioxidant capacity through the uptake of free radicals, the chelation of metals with redox properties and the modulation and inhibition of enzymatic activity.[4]

The most abundant polyphenols in cocoa are flavonoids, which have been linked to a protective effect against cardiovascular disease, decreasing the risk of cardiovascular morbidity and mortality and favouring the prevention of other chronic diseases such as diabetes mellitus type 2.[1-3, 5-7] The ability to reduce cardiovascular risk could be due to an improvement in the elements that define metabolic syndrome, the improvement of vascular endothelial dysfunction, insulin resistance and the inhibition of platelet activation and aggregation.[8, 9] However, although current evidence suggests that polyphenols produce an improvement in cardiovascular health, it is not enough to determine the minimum amount of intake necessary to achieve health benefits.[10]

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Cocoa polyphenols and blood pressure: The effect of consuming polyphenols present in chocolate on the blood pressure (BP) statistics of healthy individuals is not clear. Cocoa consumption has been associated with an improvement in endothelial function and a decrease in blood pressure in both healthy subjects and those with risk factors and cardiovascular diseases.[11, 12] Some studies have observed a dosedependent relationship between cocoa intake and clinical BP, with higher consumption equated to lower blood pressure and better vascular function.[13, 14] Conversely, other research has not obtained significant changes in these parameters related to the supplementation of cocoa or pure polyphenols such as epicatechin or quercetin.[15, 16]

Endothelial dysfunction in postmenopausal women causes changes that favour the development of cardiovascular risk factors and atherosclerosis, which lead to the appearance and maintenance of hypertension.[17, 18] A decrease in BP has been observed in this group after daily consumption of cocoa with a flavonol content of 40.12 mg. Below this level, however, no changes have been observed.[19]

Cocoa polyphenols and vascular function: Among healthy individuals as well as postmenopausal women, the consumption of polyphenols present in cocoa has been associated with a dose-dependent improvement of vascular function, in particular of arterial stiffness measured by pulse wave speed. [13, 14, 19] One of these studies also suggests that the reduction in arterial stiffness observed in postmenopausal women after consumption of cocoa is independent of the frequency of the intake.[19] However, this relationship is not evident in people with mild hypertension when cardio-ankle vascular index (CAVI) is used as a measure of arterial stiffness.[20]

There is also evidence of the influence of these polyphenols in reducing the augmentation index (Alx). The study by West et al,[21] involving subjects with excess weight and moderate obesity, concludes that the treatment with dark chocolate decreases Alx in women, although it seems that this association may affect more the

elasticity of the large arteries, especially in subjects with obesity and diabetes mellitustype 2.[22]

Cocoa polyphenols and cognitive performance: There is evidence to suggest that chocolate rich in polyphenols may be beneficial for cognitive performance and state since it improves mental processing speed and attenuates the increase of mental fatigue among healthy young adults.[23, 24] An improvement in cognitive performance among older age groups after eating chocolate has also been observed[25] and especially in subjects with higher risk of cardiovascular disease.[26] Several studies also show that polyphenol-rich chocolate causes an improvement in executive function and categorical fluency, [27] in working memory, [28, 29] and a slowing of mental fatigue[30] and also that a higher frequency of chocolate consumption has been associated with better cognitive function.[29] Furthermore, a positive influence of cocoa polyphenols on physiological processes has been reported, with a neuroprotective effect[31] and improved cognitive performance.[32] In this regard, it has been suggested that the brain-derived neurotrophic factor (BDNF) may play a role in the cognitive enhancement induced by the flavonoides.[33] Favorable effects on cerebrovascular function have also been observed in postmenopausal women after consumption of chocolate with high concentration of cocoa.[34]

Cocoa polyphenols and quality of life: The quality of life linked to health is represented by the individual's perception of well-being in various aspects of life, including physical and mental aspects. The effect of chocolate and polyphenols on the quality of life has scarcely been studied, with not a great deal of evidence available and even less of a conclusive nature. In a study conducted among healthy people, where regular consumption of chocolate was recorded over a year, no evidence was found of a clear association between chocolate intake and the physical or mental components of quality of life.[35] Nevertheless, it has been observed that the consumption of dark chocolate may be beneficial for the quality of life of women with fibromyalgia.[36]

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Coccoa polyphenols and body composition: The menopause period leads to various changes in the body composition of women.[37] Regarding the connection between cocoa polyphenols and body composition, results diverge. Some clinical trials involving healthy people and overweight or obese patients have not reported significant differences that link chocolate consumption to anthropometric measures.[16, 20, 21, 38] Other studies indicate that chocolate consumption may have positive effects on body composition in adolescents, [39] patients with diabetes [40] or women with obesity.[41] Two recent systematic reviews also indicate that eating chocolate is associated with reduced body mass index (BMI) and waist circumference, [42, 43] and one of them also concludes that the amount and the length of time during which it is eaten play a key role in these beneficial effects.[43] Conversely, other studies such as that carried out with the cohort of the Atherosclerosis Risk in Communities (ARIC) study have observed a dose-dependent increase in weight after habitual chocolate consumption.[44]

In sum, the polyphenols present in chocolate seem to have a positive effect on BP, vascular function, cognitive performance and quality of life, especially in populations with increased cardiovascular risk such as postmenopausal women.[45] However, the conflicting results obtained in different studies suggest that the real contribution of these compounds to health and the underlying mechanisms remain unclear. Moreover, most of these studies have used preparations with high concentrations of polyphenols that are usually not present in the normal diet.

This study aims to evaluate the effect of adding a daily amount of 10 g of chocolate high in cocoa content (99%) and polyphenols to the normal diet on blood pressure, vascular function, cognitive performance, quality of life and body composition in postmenopausal women.

- 162 METHODS AND ANALYSIS
- **Design and setting:**

This controlled and randomized clinical trial involves two parallel groups. The study will be carried out in the Research Unit of the La Alamedilla Health Centre in Salamanca (Spain), which is part of the Biomedical Research Institute of Salamanca (IBSAL) and the Primary Care Prevention and Health Promotion Research Network (REDIAPP). The recruitment schedule is set to start on June 1, 2018, and the study will run until May 31, 2019. There will be a baseline assessment and two follow-ups, at 3 and 6 months.

171 Study population:

Those subjects who meet the selection criteria and sign the informed consent after receiving information about the objectives and implementation of the study will take part.

175 Inclusion criteria: women between 50 and 64 years of age in postmenopause, defined
176 by and checked against amenorrhea during at least 12 consecutive months.

Exclusion criteria: personal history of cardiovascular disease; personal history of diabetes mellitus, arterial hypertension or dyslipidemia under pharmacological treatment: hypocaloric diets: clinically demonstrable neurological and/or neuropsychological disease; treatment with hormone replacement therapy; intolerance and/or allergy to cocoa or any of the components of the supplement.

Participants will be selected using a consecutive sample of women who meet the
selection criteria in the GP surgeries of four urban primary care centres in Salamanca,
from June 1, 2018.

185 Patient and public involvement

Patients and the public were not involved in the design of this study or outcome
measures. We hope that the results of the study will be disseminated through press
releases and information meetings with the study participants.

189 Sample size:

The size of the sample has been estimated based on the potential modification of themain variable, systolic blood pressure (SBP). Given alpha and beta risks of 0.05 and

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

192 0.20 respectively in bilateral contrast and a standard deviation (SD) of 5.8 mmHg, 140 193 participants (70 per group) will be necessary to detect a minimum difference of 2.9 194 mmHg in the SBP between the two groups. A predicted drop-out rate of 10% during 195 follow-up has been taken into account. This estimate has considered the results 196 obtained in a similar study in which a decrease in SBP of 6.5 was observed ± 5.8 197 mmHg.[14]

Randomization:

Participants will be assigned to the intervention group (IG) or control group (CG) at random. The allocation sequence will be generated by an independent researcher using the Epidat 4.2 program[46] and will remain hidden until the participants are assigned to each group.

203 Intervention:

204 No type of intervention will be carried out with the CG participants.

IG participants will be given chocolate with 99% cocoa content and asked to eat 10 g daily for a period of 6 months. According to the EFSA (European Food Safety Authority), 10 g of high-flavanol dark chocolate consumed in the context of a balanced diet could help maintain endothelium-dependent vasodilation.[47] Participants will also be given instructions on eating and keeping the product, with the recommendations, for example, that the chocolate can be consumed in small pieces leaving them unmated in the mouth, without chewing them. In addition, a series of recommendations will be given remembering the organoleptic characteristics of the product, as well as the recommendations of trying to consume the product at the same time or refrain from ingesting it dissolved in milk. In addition, they will be given a calendar on which to record the time it was eaten each day. This calendar will be returned to the researchers at each replenishment visit.

This amount of chocolate provides the following daily nutritional contribution: 59 Kcal,
0.8 g of carbohydrates, 1.5 g of protein, 5.1 g of fat, of which 3.1 g are saturated fats.
The proportion of polyphenols per 10 g is 65.4 mg. The polyphenolic profile of this

BMJ Open

compound can be seen in table 1. On each visit, IG participants will receive the amount of chocolate they need until the next replenishment visit. In addition to the baseline visit, there will be 5 replenishment visits in months 1, 2, 3 (coinciding with the evaluation visit), 4 and 5. The sole purpose of the replenishment visits will be to supply the amount of chocolate needed until the next visit, without any other intervention being carried out.

Participants in both groups will be instructed to continue with the dietary pattern theyusually follow, without changing their eating habits during the study period.

228 Procedures:

For each participant a baseline visit and two follow-up visits at 3 and 6 months after the initial one are scheduled (Figure 1). The IG will also make 5 replenishment visits, in months 1, 2, 3 (coinciding with the first follow-up visit), 4 and 5. In the replenishment visits they will be given the amount of chocolate needed until the next visit and will hand in the calendar with the record of the chocolate eaten.

Primary and secondary endpoints:

The primary variable will be the decrease in clinical BP, measured with a digital
sphygmomanometer. Secondary variables will include vascular function, quality of life,
cognitive performance and body composition.

All variables will be measured at 3 and 6 months after randomization, except for cognitive performance and quality of life, to be assessed only after 6 months.

240 Blood pressure:

Clinical systolic and diastolic blood pressure will be measured with a validated Omron M10-IT sphygmomanometer (Omron Healthcare, Kyoto, Japan). Three measurements will be taken in the dominant arm of the subject in a sitting position after at least 5 minutes of rest with an appropriately sized cuff, following the recommendations of the European Society of Hypertension.[48] The average of the last two measurements will be recorded.

247 Vascular function:

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The Vasera VS-2000 device (Fukuda Denshi) will be used to measure the CAVI and the brachial-ankle pulse wave velocity (ba-PWV) at rest. CAVI is a good indicator of arterial stiffness, providing an accurate estimate of the degree of atherosclerosis without depending on blood pressure.[49] CAVI \geq 9 and ba-PWV \geq 18.3 will be considered pathological.[50] Pathological CAVI is representative of subclinical atherosclerosis.[51]

254 Cognitive performance:

The instructions are presented visually at the start of the baseline measurement to ensure limiting a learning effect over the subsequent testing periods. Attention and executive functions: Trail Making Test A will be used to measure attention and Trail Making Test B for processing speed and executive functions.[52]

Immediate verbal memory will be assessed with the Rey Auditory Verbal Learning
Test. The immediate recall of a list of 15 words is measured in three attempts, followed
by delayed verbal memory through the free recall of the words learned in the first part
of the test after 10 minutes.[53]

- 263 Working memory will be assessed with the WAIS Digit Span Backward test.[54]
- 264 Phonological fluency will be explored by naming as many words as possible starting
- 265 with different letters of the FAS Questionnaire in the space of one minute.[55]
- 266 Categorical fluency measures verbal semantic fluency and will be assessed by naming
- as many animals as possible in one minute.[56]

268 Quality of life:

The quality of life linked to health will be assessed through the EuroQol 5-D questionnaire (EQ-5D). We will use the adapted Spanish version of this questionnaire, which has been validated in the Spanish population.[57] This questionnaire consists of three elements: the assessment by the individuals of their state of health in level of severity by dimension (mobility, personal care, daily activities, pain/discomfort and anxiety/depression), the assessment of their state of health on an analogue visual

Page 13 of 30

BMJ Open

scale, and finally an index of social values obtained for each state of health generatedby the instrument.

The quality of life will also be studied using the Cervantes Scale.[58] This questionnaire is specifically designed for menopause and postmenopause and has been validated for Spanish women. Its 31 structured items cover the 4 dimensions of menopause: menopause and health, sexuality, psychic domain and relationships.

281 Body composition:

Body composition will be measured with the Inbody 230 Monitor.[59] This analyzer provides data on fat mass and body fat percentage as principal outcomes and also skeletal muscle mass, total body water, fat-free mass, waist-hip ratio, basal metabolism, and a segmental analysis.

Body weight will be measured twice with an electronic scale (Scale 7830, Soehnle Professional GmbH & Co, Backnang, Germany) after proper calibration (accuracy ± 0.1 kg). Height will be measured by recording the average of two readings rounded to the nearest centimetre using a stadiometer (Seca 222, Medical scale and measurement system, Birmingham, UK). Both measurements will be made with the subject barefoot and wearing light clothing. Body mass index will be calculated by dividing weight (kg) by height squared (m²). Waist circumference will be assessed in accordance with the recommendations of the Spanish Society for the Study of Obesity (SEEDO)[60] and will be measured in duplicate before and after inhalation, using a flexible tape parallel to the floor, at the level of the mid-point between the lowest rib and the iliac crest, with the subject standing up and without clothes.

- 297 Other variables
- 298 Clinical and sociodemographic variables

At the baseline visit, information on clinical and sociodemographic variables will also be collected via questions about age, marital status, educational level and occupation. Family history of cardiovascular disease and personal history of anxiety and/or

depression, gestational diabetes, hypertension, dyslipidemia and the prescribed
pharmacological treatment (antiaggregants, anticoagulants, thyroid hormone treatment,
anxiolytics) will also be recorded, as well as the taking of NSAIDs in the last two weeks.
In subsequent visits, personal histories of cardiovascular disease, diabetes mellitus,
arterial hypertension or dyslipidemia in treatment, as well as the prescribed
pharmacological treatment (hypolipidemic, antihypertensive, antidiabetic) will also be

309 Evaluation of chocolate consumption and habitual diet

310 Chocolate consumption will be assessed at each evaluation visit by a series of 311 questions about the amount, type and frequency of consumption in the period between 312 visits.

Nutritional habits will be assessed by a 24-hour log on 3 non-consecutive days prior to
each visit.

315 Evaluation of other lifestyles

The use of tobacco will be assessed with a questionnaire on the personal history and

317 pattern of smoking.

318 Alcohol use will be recorded with a questionnaire covering the previous 7 days which 319 will include specific beverages and the amount by volume drunk of each.

Physical activity will be measured using the International Physical Activity Questionnaire (IPAQ) in its short version and validated in Spanish.[61] This questionnaire measures activity over the previous 7 days, classifying the subjects according to three activity levels (low, moderate and high) with respect to three types of activities: walking, moderate-intensity activities and vigorous-intensity activities. The amount of physical exercise will be estimated in METs-minute/week.

326 Evaluation of laboratory variables

At baseline and follow-up visits at 6 months, we will measure plasma fasting glucose values (mg/dL), glycated haemoglobin (%), total cholesterol (mg/dL), total triglycerides (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), creatinine (mg/L),

BMJ Open

insulinemia (mg/dL). Creatinine in urine (mg/dL) and microalbuminuria (mg/dL) will also
be measured. Insulin resistance will be determined using the HOMA index
(Homeostasis Model Assessment Insulin Resistance) estimated using the following
equation: Fasting glucose (mmol/l) X insulin (mU/ml)/22.5.

The evaluation visits will be made in the morning between 8:00 and 10:00 a.m. Each participant will be informed prior to the visit to go fasting for at least 12 hours, having avoided the 24 hours prior to visiting the consumption of polyphenol-rich foods, including cocoa, chocolate, apples, and red wine as well as alcoholic drinks or the performance of programmed physical activity. All evaluation visits, including blood pressure measurements and evaluations of vascular function, will be carried out in a room with conditions of lighting and temperature standardized, recommending that patients attend the appointment with a prior rest of at least 8- 10 hours.

Data collection procedure, data management and monitoring

Data collection of the baseline and follow-up evaluation visits at 3 and 6 months will be carried out by a nurse specifically trained to do so. The intervention visit after the baseline evaluation will be carried out by another nurse, different from the one who does the data collection. Each participant will have a unique identification code within the study. All measurements will be compiled in a data collection notebook and kept in a secure place that will remain closed within the health center. A database will be created in SPSS to which only the members of the research team and the people related to the statistical analyzes will have access. The principal investigator or a person designated for this purpose will perform a weekly process of monitoring the study, taking into account the inclusion of patients, cleaning and debugging of databases and adaptation of the procedures to the protocol.

354 Blinding strategy:

355 Due to the nature of the intervention itself, the participants and the person responsible 356 for delivering the chocolate to IG participants, cannot be blinded. However, the person BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

3
4
5
6
7
, 8
9
10
11
12
13
14
15
16
16 17
18
19
20
20
∠ I วว
22 23
23
24
25
26
27
28
29
30
31 32 33
33
22
34
35
36 37
37
38
39
40
41
42
43
44
45
45 46
47
48
49
50
51
52
53
54
55
56
57
58
50 59
60

1 2

responsible for carrying out the study measurements at each visit and for the statisticalanalysis will be blind to the intervention.

359 Statistical analysis:

360 General analysis

361 Results for the quantitative variables will be expressed by mean ± standard deviation or 362 by frequency distribution in the case of qualitative ones. The normality of the variables 363 will be assessed using the Kolmogorov-Smirnov test. In cases where a normal 364 distribution cannot be assumed, the corresponding nonparametric tests will be applied. 365 The association between independent qualitative variables will be analyzed by means 366 of the chi-square test or Fisher's exact test. The means between the two groups will be 367 compared using the Student's t test or the Mann-Whitney U test, and the Pearson or 368 Spearman correlation coefficients will be calculated to analyze the relationship between 369 quantitative variables.

The analysis of the results for the main variable and the secondary variables will be carried out by intention to treat. In addition, a secondary analysis will be run taking into account chocolate intake adherence (< 50% days and > 50% days) and other relevant subgroups in relation to their physical activity or previous chocolate consumption.

374 All analyses will be performed with the SPSS version 23.0 (IBM Corporation, Armonk,

375 NY, USA) and an alpha risk of 0.05 will be set as the limit of statistical significance.

376 Analysis of the intervention's effect on primary and secondary outcomes.

To analyze the changes at 3 and 6 months from baseline in the primary outcome (blood pressure) and in the secondary outcomes within the same group, the Student's t test for paired data or the Wilcoxon test will be used. The McNemar test will be applied with quantitative or dichotomous variables.

Effects of the intervention will be analyzed in a comparison of the changes in blood pressure and the secondary variables between the IG and the CG, using ANCOVA and adjusting for possible confounders as the smoking status. Effects of the intervention during follow-up will be studied with an analysis of the variance of repeated measures.

385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410

85 Analysis by subgroups.

The effect of the intervention could be influenced by age, sociocultural level and adherence to the study's chocolate intake. The same analyses described above will be performed for each of the aforementioned subgroups.

389 Secondary analyses.

A multivariate multiple regression analysis will be performed to identify the variables
with the greatest influence on blood pressure changes and the secondary variables
analyzed.

393 Methodological limitations:

Due to the nature of the intervention, the participating subjects cannot be blinded. However, the researcher who analyses the data and the person who makes the measurements during follow-up visits will be blinded with respect to the group to which the participants belong. The smoking status in the 12 months prior to the time of inclusion could influence the outcome measures related to vascular function and blood pressure so, although participants will not be excluded for this reason, this aspect will be controlled in statistical analysis. Assessment of the quality of life and lifestyles will be carried out through self-reported data; however, previously validated instruments will be used to obtain these. To make compliance with the intervention in the IG easier, IG participants will be provided with instructions on eating the chocolate and a calendar to record each intake.

405 ETHICS AND DISSEMINATION

Ethical considerations:

The study was approved by the Clinical Research Ethics Committee of the Salamanca
Health Area ("CREC of Health Area of Salamanca") in February 2018. A SPIRIT
checklist is available for this protocol. The clinical trial has been registered at
ClinicalTrials.gov with the identifier NCT03492983.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Participants must sign informed consent in accordance with the Declaration of Helsinki.
Subjects will be informed of the objectives of the project and the risks and benefits of
the explorations to be carried out, including sample collection. None of the tests will
pose risks that could endanger the lives of participants. Confidentiality of participant
data will be guaranteed at all times in accordance with the provisions of the Organic
Law on the Protection of Personal Data (15/1999 of December 13, LOPD), and under
the conditions established by Law 14/2007 of biomedical research.

Dissemination plan:

The research group plans to achieve rapid and widespread dissemination of results to ensure maximum visibility of this study. To this end, the results of the study will be published in open-access scientific journals with peer review. At least one publication of the main results and others with the secondary results are planned. This will be complemented by presentation of the results of the study at relevant scientific conferences and seminars of national and international scope. In addition, a doctoral thesis based on this project will be prepared. Appropriate dissemination will likewise be carried out through social networks and other media. Moreover, given the involvement of a commercial product, the transfer to clinical practice is expected to be very fast if the results are as expected.

DISCUSSION

In recent years, there has been an increase in attention to polyphenols and their beneficial effects on health, with numerous studies being carried out to assess this.[19, 21] Similarly, the therapeutic use of these compounds has been suggested for certain diseases or population groups.[36, 62] The menopause increases the risk of developing cardiovascular disease compared to the previous period. [45] However, we have not found any study that assesses the effect of adding commercially available chocolate high in cocoa content to the usual diet in this population at special risk. Similarly, no studies have been found that evaluate the effects on cognitive

performance, quality of life and body composition of adding commercial chocolate withhigh cocoa content to the usual diet in postmenopausal women.

The results of this work will provide new evidence in this regard for the development of strategies in nutritional education of particularly vulnerable populations, given their high risk of developing cardiovascular disease, including non-pharmacological therapies and strategies that employ lifestyle modification. This intervention may also have implications for the preparation of recommendations in clinical practice guidelines and ment program. quality improvement programs aimed at the care of postmenopausal women.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

REFERENCES

447	1. Grassi D, Desideri G, Ferri C. Flavonoids: antioxidants against atherosclerosis. Nutrients
448	2010;2(8):889-902. doi: 10.3390/nu2080889 [published Online First: 2010/08/01]
449	2. Grassi D, Desideri G, Croce G, et al. Flavonoids, vascular function and cardiovascular
450	protection. Curr Pharm Des 2009;15(10):1072-84. [published Online First: 2009/04/10]
451	3. Visioli F, Bernaert H, Corti R, et al. Chocolate, lifestyle, and health. Crit Rev Food Sci Nutr
452	2009;49(4):299-312. doi: 10.1080/10408390802066805 [published Online First:
453	2009/02/24]
454	4. Cos P, De Bruyne T, Hermans N, et al. Proanthocyanidins in health care: current and new
455	trends. Curr Med Chem 2004;11(10):1345-59. [published Online First: 2004/05/12]
456	5. Grassi D, Desideri G, Ferri C. Blood pressure and cardiovascular risk: what about cocoa and
457	chocolate? Arch Biochem Biophys 2010;501(1):112-5. doi: 10.1016/j.abb.2010.05.020
458	[published Online First: 2010/05/25]
459	6. Mink PJ, Scrafford CG, Barraj LM, et al. Flavonoid intake and cardiovascular disease
460	mortality: a prospective study in postmenopausal women. Am J Clin Nutr
461	2007;85(3):895-909. doi: 10.1093/ajcn/85.3.895 [published Online First: 2007/03/09]
462	7. Ramos S, Martin MA, Goya L. Effects of Cocoa Antioxidants in Type 2 Diabetes Mellitus.
463	Antioxidants (Basel) 2017;6(4) doi: 10.3390/antiox6040084 [published Online First:
464	2017/11/01]
465	8. Osakabe N. Flavan 3-ols improve metabolic syndrome risk factors: evidence and
466	mechanisms. J Clin Biochem Nutr 2013;52(3):186-92. doi: 10.3164/jcbn.12-130
467	[published Online First: 2013/05/25]
468 469	9. Engler MB, Engler MM, Chen CY, et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. <i>J Am Coll</i>
409 470	Nutr 2004;23(3):197-204. [published Online First: 2004/06/11]
470	10. Ottaviani JI, Heiss C, Spencer JPE, et al. Recommending flavanols and procyanidins for
471	cardiovascular health: Revisited. <i>Mol Aspects Med</i> 2018;61:63-75. doi:
472	10.1016/j.mam.2018.02.001 [published Online First: 2018/02/11]
474	11. Ludovici V, Barthelmes J, Nagele MP, et al. Cocoa, Blood Pressure, and Vascular Function.
475	Front Nutr 2017;4:36. doi: 10.3389/fnut.2017.00036 [published Online First:
476	2017/08/22]
477	12. Ried K, Fakler P, Stocks NP. Effect of cocoa on blood pressure. <i>Cochrane Database Syst Rev</i>
478	2017;4:CD008893. doi: 10.1002/14651858.CD008893.pub3 [published Online First:
479	2017/04/26]
480	13. Heiss C, Sansone R, Karimi H, et al. Impact of cocoa flavanol intake on age-dependent
481	vascular stiffness in healthy men: a randomized, controlled, double-masked trial. Age
482	(Dordr) 2015;37(3):9794. doi: 10.1007/s11357-015-9794-9 [published Online First:
483	2015/05/28]
484	14. Grassi D, Desideri G, Necozione S, et al. Cocoa consumption dose-dependently improves
485	flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy
486	individuals. J Hypertens 2015;33(2):294-303. doi: 10.1097/hjh.000000000000412
487	[published Online First: 2014/11/08]
488	15. Crews WD, Jr., Harrison DW, Wright JW. A double-blind, placebo-controlled, randomized
489	trial of the effects of dark chocolate and cocoa on variables associated with
490	neuropsychological functioning and cardiovascular health: clinical findings from a
491	sample of healthy, cognitively intact older adults. Am J Clin Nutr 2008;87(4):872-80.
492	[published Online First: 2008/04/11]
493	16. Dower JI, Geleijnse JM, Gijsbers L, et al. Effects of the pure flavonoids epicatechin and
494	quercetin on vascular function and cardiometabolic health: a randomized, double-
495	blind, placebo-controlled, crossover trial. Am J Clin Nutr 2015;101(5):914-21. doi:
496	10.3945/ajcn.114.098590 [published Online First: 2015/05/03]
	18
	For peer review only - http://bmiopen.hmi.com/site/about/guidelines.xhtml

BMJ Open

2		
3	497	17. Modena MG. Hypertension in postmenopausal women: how to approach hypertension in
4	498	menopause. High Blood Press Cardiovasc Prev 2014;21(3):201-4. doi: 10.1007/s40292-
5	499	014-0057-0 [published Online First: 2014/05/24]
6	500	18. Zilberman JM, Cerezo GH, Del Sueldo M, et al. Association Between Hypertension,
7	501	Menopause, and Cognition in Women. J Clin Hypertens (Greenwich) 2015;17(12):970-
8	502	6. doi: 10.1111/jch.12643 [published Online First: 2015/08/08]
9	503	19. Okamoto T, Kobayashi R, Natsume M, et al. Habitual cocoa intake reduces arterial stiffness
10	505	in postmenopausal women regardless of intake frequency: a randomized parallel-
11	505	group study. <i>Clin Interv Aging</i> 2016;11:1645-52. doi: 10.2147/cia.s118152 [published]
12	505	
13		Online First: 2016/11/25]
14	507	20. Koli R, Kohler K, Tonteri E, et al. Dark chocolate and reduced snack consumption in mildly
15	508	hypertensive adults: an intervention study. Nutr J 2015;14:84. doi: 10.1186/s12937-
16	509	015-0075-3 [published Online First: 2015/08/25]
17	510	21. West SG, McIntyre MD, Piotrowski MJ, et al. Effects of dark chocolate and cocoa
18	511	consumption on endothelial function and arterial stiffness in overweight adults. Br J
19	512	Nutr 2014;111(4):653-61. doi: 10.1017/s0007114513002912 [published Online First:
20	513	2013/11/28]
21	514	22. Basu A, Betts NM, Leyva MJ, et al. Acute Cocoa Supplementation Increases Postprandial
22	515	HDL Cholesterol and Insulin in Obese Adults with Type 2 Diabetes after Consumption
23	516	of a High-Fat Breakfast. J Nutr 2015;145(10):2325-32. doi: 10.3945/jn.115.215772
24	517	[published Online First: 2015/09/05]
25	518	23. Scholey AB, French SJ, Morris PJ, et al. Consumption of cocoa flavanols results in acute
26	519	improvements in mood and cognitive performance during sustained mental effort. J
27	520	Psychopharmacol 2010;24(10):1505-14. doi: 10.1177/0269881109106923 [published
28	521	Online First: 2009/11/28]
29	522	24. Field DT, Williams CM, Butler LT. Consumption of cocoa flavanols results in an acute
30	523	improvement in visual and cognitive functions. Physiol Behav 2011;103(3-4):255-60.
31	524	doi: 10.1016/j.physbeh.2011.02.013 [published Online First: 2011/02/18]
32	525	25. Sorond FA, Hurwitz S, Salat DH, et al. Neurovascular coupling, cerebral white matter
33	526	integrity, and response to cocoa in older people. Neurology 2013;81(10):904-9. doi:
34	527	10.1212/WNL.0b013e3182a351aa [published Online First: 2013/08/09]
35	528	26. Socci V, Tempesta D, Desideri G, et al. Enhancing Human Cognition with Cocoa Flavonoids.
36	529	Front Nutr 2017;4:19. doi: 10.3389/fnut.2017.00019 [published Online First:
37	530	2017/06/01]
38	531	27. Mastroiacovo D, Kwik-Uribe C, Grassi D, et al. Cocoa flavanol consumption improves
39	532	cognitive function, blood pressure control, and metabolic profile in elderly subjects:
40	533	the Cocoa, Cognition, and Aging (CoCoA) Studya randomized controlled trial. Am J
41	534	<i>Clin Nutr</i> 2015;101(3):538-48. doi: 10.3945/ajcn.114.092189 [published Online First:
42	535	2015/03/04]
43	536	28. Grassi D, Socci V, Tempesta D, et al. Flavanol-rich chocolate acutely improves arterial
44	537	function and working memory performance counteracting the effects of sleep
45		
46	538	
47	539	10.1097/hjh.00000000000926 [published Online First: 2016/04/19]
48	540	29. Crichton GE, Elias MF, Alkerwi A. Chocolate intake is associated with better cognitive
49 50	541	function: The Maine-Syracuse Longitudinal Study. <i>Appetite</i> 2016;100:126-32. doi:
50 51	542	10.1016/j.appet.2016.02.010 [published Online First: 2016/02/14]
52	543	30. Massee LA, Ried K, Pase M, et al. The acute and sub-chronic effects of cocoa flavanols on
52	544	mood, cognitive and cardiovascular health in young healthy adults: a randomized,
55 54	545	controlled trial. Front Pharmacol 2015;6:93. doi: 10.3389/fphar.2015.00093 [published
55	546	Online First: 2015/06/05]
56		
57		
58		
59		19
-		

31. Nehlig A. The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. Br J Clin Pharmacol 2013;75(3):716-27. doi: 10.1111/j.1365-2125.2012.04378.x [published Online First: 2012/07/11] 32. Nurk E, Refsum H, Drevon CA, et al. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr 2009;139(1):120-7. doi: 10.3945/jn.108.095182 [published Online First: 2008/12/06] 33. Neshatdoust S, Saunders C, Castle SM, et al. High-flavonoid intake induces cognitive improvements linked to changes in serum brain-derived neurotrophic factor: Two randomised, controlled trials. Nutr Healthy Aging 2016;4(1):81-93. doi: 10.3233/nha-1615 [published Online First: 2016/12/31] 34. Marsh CE, Carter HH, Guelfi KJ, et al. Brachial and Cerebrovascular Functions Are Enhanced in Postmenopausal Women after Ingestion of Chocolate with a High Concentration of Cocoa. J Nutr 2017;147(9):1686-92. doi: 10.3945/jn.117.250225 [published Online First: 2017/08/11] 35. Balboa-Castillo T, Lopez-Garcia E, Leon-Munoz LM, et al. Chocolate and health-related quality of life: a prospective study. *PLoS One* 2015;10(4):e0123161. doi: 10.1371/journal.pone.0123161 [published Online First: 2015/04/23] 36. Costa de Miranda R, Paiva ES, Suter Correia Cadena SM, et al. Polyphenol-Rich Foods Alleviate Pain and Ameliorate Quality of Life in Fibromyalgic Women. Int J Vitam Nutr Res 2016:1-10. doi: 10.1024/0300-9831/a000253 [published Online First: 2016/11/22] 37. Dmitruk A, Czeczelewski J, Czeczelewska E, et al. Body composition and fatty tissue distribution in women with various menstrual status. Rocz Panstw Zakl Hig 2018;69(1):95-101. [published Online First: 2018/03/10] 38. Davison K, Coates AM, Buckley JD, et al. Effect of cocoa flavanols and exercise on cardiometabolic risk factors in overweight and obese subjects. Int J Obes (Lond) 2008;32(8):1289-96. doi: 10.1038/ijo.2008.66 [published Online First: 2008/05/28] 39. Cuenca-Garcia M, Ruiz JR, Ortega FB, et al. Association between chocolate consumption and fatness in European adolescents. *Nutrition* 2014;30(2):236-9. doi: 10.1016/j.nut.2013.07.011 [published Online First: 2013/10/22] 40. Ayoobi N, Jafarirad S, Haghighizadeh MH, et al. Protective Effect of Dark Chocolate on Cardiovascular Disease Factors and Body Composition in Type 2 Diabetes: A Parallel, Randomized, Clinical Trial. Iran Red Crescent Med J 2017;19(8):e21644. doi: 10.5812/ircmj.21644 [published Online First: 2017-08-01] 41. Di Renzo L, Rizzo M, Sarlo F, et al. Effects of dark chocolate in a population of normal weight obese women: a pilot study. Eur Rev Med Pharmacol Sci 2013;17(16):2257-66. [published Online First: 2013/07/31] 42. González-Sarrías A, Combet E, Pinto P, et al. A Systematic Review and Meta-Analysis of the Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. Nutrients 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. Crit Rev Food Sci Nutr 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a One 2013;8(8):e70271. dose-response manner. PLoS doi: 10.1371/journal.pone.0070271 [published Online First: 2013/08/21] 45. Agrinier N, Cournot M, Dallongeville J, et al. Menopause and modifiable coronary heart disease risk factors: a population based study. Maturitas 2010;65(3):237-43. doi: 10.1016/j.maturitas.2009.11.023 [published Online First: 2009/12/25]

BMJ Open


2		
3	598	46. Consellería de Sanidade Xunta de Galicia. Spain; Pan American Organization health (PAHO-
4	599	WHO); CES University C. Epidat: program for epidemiological data analysis. Version
5	600	4.2Julio 2016.
6	601	47. Scientific Opinion on the substantiation of a health claim related to cocoa flavanols and
7	602	maintenance of normal endothelium-dependent vasodilation pursuant to Article 13(5)
8	603	of Regulation (EC) No 1924/2006. <i>EFSA Journal</i> 2012;10(7):2809. doi:
9	604	doi:10.2903/j.efsa.2012.2809
10	605	48. 2013 Practice guidelines for the management of arterial hypertension of the European
11	606	Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC
12	607	Task Force for the Management of Arterial Hypertension. J Hypertens
13	608	2013;31(10):1925-38. doi: 10.1097/HJH.0b013e328364ca4c [published Online First:
14	609	2013/10/11]
15	610	49. Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of
16	611	arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb
17	612	2011;18(11):924-38. [published Online First: 2011/06/02]
18	613	50. Ohkuma T, Tomiyama H, Ninomiya T, et al. Proposed Cutoff Value of Brachial-Ankle Pulse
19	614	Wave Velocity for the Management of Hypertension. <i>Circ J</i> 2017;81(10):1540-42. doi:
20	615	10.1253/circj.CJ-17-0636 [published Online First: 2017/08/25]
21		
22	616	51. Korkmaz L, Erkan H, Korkmaz AA, et al. Relationship of aortic knob width with cardio-ankle
23	617	vascular stiffness index and its value in diagnosis of subclinical atherosclerosis in
24	618	hypertensive patients: a study on diagnostic accuracy. Anadolu Kardiyol Derg
25	619	2012;12(2):102-6. doi: 10.5152/akd.2012.034 [published Online First: 2012/01/28]
26	620	52. Reitan RM. Trail Making Test. Tucson: Reitan Neuropsychology Laboratory 1992.
27	621	53. Rey A. L'examen clinique en psychologie. Paris: Presses universitaires de France 1964.
28	622	54. Wechsler D. WMS-R Wechsler memory scale. San Antonio, Texas: The Psychological
29	623	Corporation 1987.
30	624	55. Valencia NJ, Laserna, J. A., Pérez-García, M., Orozco, C., Miñán, M., Garrido, C., Morente, G.
31	625	Influencia de la escolaridad y el sexo sobre la ejecución en el FAS, nombrar animales y
32	626	nombrar frutas. <i>Psicología Conductual</i> 2000;8(2):283-95.
33	627	56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986.
34	628	57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQoI 5-D in the Catalan general
35	629	population: feasibility and construct validity. Qual Life Res 1998;7(4):311-22.
36	630	[published Online First: 1998/06/04]
37	631	58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish
38	632	women through and beyond menopause. Development and validation of the
39 40	633	Cervantes Scale]. Med Clin (Barc) 2004;122(6):205-11. [published Online First:
40 41	634	2004/03/12]
41	635	59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable
42	636	bioelectrical impedance analyzer for the assessment of body composition. Appl Physiol
44	637	Nutr Metab 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First:
45	638	2013/02/02]
45	639	60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation of
47	640	overweight and obesity and the establishment of therapeutic intervention criteria].
48	641	Med Clin (Barc) 2007;128(5):184-96; quiz 1 p following 200. [published Online First:
49	642	2007/02/15]
50	643	61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity
51	643 644	questionnaire in the Catalan population (Spain)]. Gac Sanit 2013;27(3):254-7. doi:
52		
53	645	10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30]
54	646	62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating
55	647 648	Inflammation and Oxidation-Mediated Degenerative Diseases. Oxid Med Cell Longev
56	648	2016;2016:5137431. doi: 10.1155/2016/5137431 [published Online First: 2016/10/11]
57		
58		21
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

649	
650	AUTHORS' CONTRIBUTIONS:
651	JIR, JAM, LGO and IGY contributed to the conception and design of the study. IGY,
652	JIR and JAM prepared the manuscript of the study protocol. JIR, JAM, LGO, RAD,
653	SMS, JGS, SMG, ERS, MGM and IGY contributed to the development of the study
654	protocol. JIR, JAM, LGO, RAD, SMS, JGS, SMG, ERS, MGM and IGY provided
655	assistance with statistical methodology and knowledge. JIR, JAM, LGO, RAD, SMS,
656	JGS, SMG, ERS, MGM and IGY provided a critical review of the manuscript.
657	All authors have read and accepted the final version of the protocol.
658	FUNDING STATEMENT:
659	This study was supported in part by grants funded by la Gerencia Regional de Castilla
660	y León (GRS 1583/B/17).
661	"Lindt & Sprüngli will provide the necessary chocolate for the implementation of the
662	study. This company will not play any role in the design of the study, data analysis,
663	reporting of results, or the decision to present the manuscript for publication".
664	COMPETING INTERESTS STATEMENT:
665	The authors declare that they have no conflicts of interest.
666	ACKNOWLEDGMENTS:
667	The authors are grateful to all the professionals involved in the ECCAMP study:
668	José I Recio-Rodríguez, José A Maderuelo-Fernández, Luis García-Ortiz, Manuel A
669	Gómez-Marcos, Irene A García-Yu, Rosario Alonso-Domínguez, Sara Mora-Simón,
670	Natalia Sánchez-Aguadero, Jesús González-Sánchez, Cristina Agudo-Conde, Cristina
671	Lugones-Sánchez, Benigna Sánchez-Salgado, Carmen Castaño-Sánchez, Emiliano
672	Rodríguez-Sánchez, Susana González-Manzano, Olaya Tamayo-Morales, Susana
673	González-Sánchez.
674	FIGURE LEGEND:
675	Figure 1. Study flow chart
676	Table 1. Polyphenol composition of 99% cocoa chocolate

677	,	
678	Table 1. Polyphenols compos	ition of 99% cocoa chocolate.
	Compounds	Quantity
	Protocatechuic acid (mg/g)	0.058 ± 0.008
	Procyanidin dimer (B3) (mg/g)	0.176 ± 0.013
	Catechin (mg/g)	1.035 ± 0.105
	Procyanidin dimer (B2) (mg/g)	1.440 ± 0.055
	Epicatechin (mg/g)	2.610 ± 0.075
	Procyanidin trimer (C1) (mg/g)	0.853 ± 0.024
	Procyanidin A hexoside (mg/g)	0.354 ± 0.007
	Quercetin glucoside (mg/g)	0.002 ± 0.000
	Quercetin arabinoside (mg/g)	0.003 ± 0.001
79)	
	For peer review only - h	nttp://bmjopen.bmj.com/site/abou
	i or peer review only - I	http://binjopen.binj.com/site/abot

Page 26 of 30

BMJ Open





STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormatior		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Pag 1, line 1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Pag 2, line 50
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	Pag 22, line 659
Roles and	5a	Names, affiliations, and roles of protocol contributors	Pag 22, line 651
responsibilities	5b	Name and contact information for the trial sponsor	Pag 22, line 659
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Pag 22, line 662
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Pag 22, line 651
	.6	BBS) . Protected by copyrightarge, المانية: المانية: المانية: المانية: عامانية: عامانية: عامانية: عامانية: عامانية: Protected by copyrightarge) . Protected by copyrightarge, المانية: عامانية: عامانية: عامانية: عامانية: عامانية: عامانية: عامانية: عامانية: عام	

BMJ Open: first published as 10.50% at Agence Bibliographical transmission 14 December 2018. Downloaded from http://mgipen.bml.com/ on June 7, 2025 at Agence Bibliographique de l

2					
3 4	Introduction				
5 6 7	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Pag 6, line 151	
8		6b	Explanation for choice of comparators	Pag 6, line 151	
9 10	Objectives	7	Specific objectives or hypotheses	Pag 6, line 158	
11 12 13 14	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Pag 7, line 164	
15 16	Methods: Participa	nts, inte	erventions, and outcomes		
17 18 19	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Pag 7, line 164	
20 21 22	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Pag 7, line 175	
23 24 25	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Pag 8, line 204	
26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA	
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	Pag 8, line 214	
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	Pag 8, line 208	
34 35 36 37 38 39 40 41 42 43	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Pag 9, line 235	
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1	0
					2
44 45 46 47	l əb əupidqsıgoildi8 əɔr		a s 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://mjopen.bmj.com/ on June 7, 202 Enseignement Superieur (SBBA) . Protected by copyrightyageluiding.formeres ปลุปลาย (Astandiquer de training.agd.similar technologies	Asilduq tərif :nəqC	BW1

Page	29	of	30
------	----	----	----

BMJ Open

2 3 4	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Pag 7, line 190	
5 6 7	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	Pag 7, line 182	
, 8 9	Methods: Assignm	ent of i	nterventions (for controlled trials)		
10 11	Allocation:				
12 13 14 15 16	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Pag 8, line 199	
17 18 19 20	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Pag 8, line 199	
21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Pag 8, line 200	
24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Pag 13, line 355	
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Pag 13, line 355	
30 31	Methods: Data coll	ection,	management, and analysis		
32 33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Pag 9, line 238	
38 39 40		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	NA	
41 42 43					3
44 45 46	l əb əupirlqsıgoildi8 əɔr		ed as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 Enseignement Superieur (BBB) . Protected by copyright,/ສູສຣູແກ່ເຊາະອິງສູເອງເອງ ອີງອີງອີງອີງອີງອີງອີງອີງອີງອີງອີງອີງອີງອ	Asilduq first îneqO	เพย

2 3 4 5	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Pag 13, line 343	
6 7 8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Pag 14, line 377	
9 10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Pag 15, line 385	
11 12 13 14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	Pag 15, line 387	
15 16	Methods: Monitorin	g			
17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	NA	
22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA	
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	NA	
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA	
31 32	Ethics and dissemin	nation			
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Pag 15, line 407	
37 38 39 40	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	NA	
41 42 43					4
44			a Salawaa unuu Felimpersiewiew onlisuhtte://bmienen.hmicenn.hmicenn/site/about/unsidelines.ystral.(doo.(a.popooo)		
45 46 47 I	əb əupidqraphique de		a as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 202 Enseignement Superieur (ABES) . Protected by copyright,ผู้ต่อไม่ผู้คุญญญญาหรือรุษิตรุษระดุริษณ์อยู่ได้สุรุ/ญญัญญี่ได้ หลี่ทุ่มัญรอยดี similar technologie	Open: first publish	BMJ

BMJ Open

$\begin{matrix} 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 9 \\ 40 \\ 41 \end{matrix}$	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Pag 16, line 411			
		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA			
	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Pag 16, line 414			
	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Pag 22, line 665			
	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Pag 13, line 349			
	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA			
	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Pag 16, line 419			
		31b	Authorship eligibility guidelines and any intended use of professional writers	Pag 16, line 419			
		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Pag 16, line 426			
	Appendices						
	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA			
	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA			
	*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons " <u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u> " license.						
42 43				5			
44	For page wight only the http://brainpap.hmi.com/cita/about/grainalines.yhtml of a						
tirst published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I 90 123 - Protected by copyright,#seluppingringrees/selafced forext.and/data/mingr.abd/similar technologies.							

BMJ Open

Vascular and cognitive effects of cocoa-rich chocolate in postmenopausal women: A study protocol for a randomized clinical trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-024095.R2
Article Type:	Protocol
Date Submitted by the Author:	03-Oct-2018
Complete List of Authors:	Garcia-Yu, Irene; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); Consejería de Sanidad, Junta de Castilla y León, Public Health Information Garcia-Ortiz, Luis; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Department of Biomedical and Diagnostic Sciences Gomez-Marcos, Manuel; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Medicine Alonso-Dominguez, Rosario; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL) González-Sánchez, J; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACYL) González-Sánchez, J; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACYL); University of Extremadura, Nursing Mora-Simon, Sara; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, Basic Psychology, Psychobiology and Behavioral Sciences Methodology González-Manzano, Susana; University of Salamanca, Analytical Chemistry Rodriguez-Sanchez, Emiliano; Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL); University of Salamanca, IBSAL), Primary Health Care Research Unit, La Alamedilla Health Center. Health Service of Castilla y León (SACyL) Recio-Rodriguez, Jose; Institute of Biomedical Researc
Primary Subject	Nutrition and metabolism

1 2 3 4 5 6	
3 4	Hea
5	Secondary Subje
6 7	
8	
9 10	
11	t.
12 13	
14	
15 16	
17	
18 19	
20	
21 22	
23	
24 25	
26	
27 28	
29	
30 31	
32	
33 34	
35	
36 37	
38	
39 40	
41	
42 43	
44	
45 46	
47	
48 49	
50	
51 52	
53	
54 55	
56	
57 58	
59	-
60	For

Heading:	
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	chocolate, postmenopause, arterial pressure, vascular stiffness, body composition, quality of life
	SCHOLARONE [™]
	Manuscripts
_	
For peer review	only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 2 of 32

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

effects

of

cocoa-rich chocolate

in

and cognitive

TITLE: Vascular

2	postmenopausal women: A study protocol for a randomized clinical trial.
3	AUTHORS:
4	Irene A Garcia-Yu ^{1,2} , Luis Garcia-Ortiz ^{1,3} , Manuel A Gómez-Marcos ^{1,4} , Rosario Alonso-
5	Dominguez ¹ , Jesus Gonzalez-Sanchez ^{1,5} , Sara Mora-Simon ^{1,6} , Susana González-
6	Manzano ⁷ , Emiliano Rodriguez-Sanchez ^{1,4} , Jose A Maderuelo-Fernandez ¹ *, Jose I
7	Recio-Rodriguez ^{1,8} *
8	1. Institute of Biomedical Research of Salamanca (IBSAL), Primary Health Care
9	Research Unit, La Alamedilla Health Center. Health Service of Castilla y León
10	(SACyL), Salamanca, Spain.
11	2. Public Health Information Service, Consejería de Sanidad, Junta de Castilla y León,
12	Valladolid, Spain.
13	3. Department of Biomedical and Diagnostic Sciences, University of Salamanca,
14	Salamanca, Spain.
15	4. Department of Medicine, University of Salamanca, Salamanca, Spain.
16	5. Department of Nursing, University of Extremadura, Plasencia, Spain.
17	6. Department of Basic Psychology, Psychobiology and Behavioral Sciences
18	Methodology, University of Salamanca, Salamanca, Spain.
19	7. Department of Analytical Chemistry, University of Salamanca, Salamanca, Spain.
20	8. Faculty of Health Sciences, University of Burgos, Burgos, Spain.
21	*These authors contributed equally to this work.
22	CORRESPONDING AUTHOR:
23	Irene A Garcia-Yu
24	Primary Care Research Unit, The Alamedilla Health Centre. 37003 Salamanca, Spain.
25	ireneailinggarciayu@gmail.com
26	0034923231859

Page 3 of 32

BMJ Open

27 ABSTRACT

Introduction: The intake of polyphenols has certain health benefits. This study will aim to assess the effect of adding a daily amount of chocolate high in cocoa content and polyphenols to the normal diet on blood pressure, vascular function, cognitive performance, quality of life and body composition in postmenopausal women.

Methods and analysis: Here we plan a randomized clinical trial with two parallel groups involving a total of 140 women between 50- and 64-years-old in the postmenopausal period, defined by amenorrhea of at least 12 consecutive months. The main variable will be the change in blood pressure. Secondary variables will be changes in vascular function, quality of life, cognitive performance, and body composition. The intervention group will be given chocolate containing 99% cocoa, with instructions to add 10 g daily to their normal diet for 6 months. The daily nutritional contribution of this amount of chocolate is 59 Kcal and 65.4 mg of polyphenols. There will be no intervention in the control group. All variables will be measured at the baseline visit and 3 and 6 months after randomization, except cognitive performance and quality of life, which will only be assessed at baseline and at 6 months. Recruitment is scheduled to begin on June 1, 2018, and the study will continue until May 31, 2019.

Ethics and dissemination: This study was approved by the Clinical Research Ethics Committee of the Health Area of Salamanca, Spain ("CREC of Health Area of Salamanca") in February 2018. A SPIRIT checklist is available for this protocol. The clinical trial has been registered at ClinicalTrials.gov provided by the US National Library of Medicine, number NCT03492983. The results will be disseminated through open access peer-reviewed journals, conference presentations, broadcast media, and a presentation to stakeholders.

Keywords: Chocolate, postmenopause, arterial pressure, vascular stiffness, body 53 composition, quality of life.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.



56 Strengths and limitations of this study:

This study will use commercially available chocolate with a high content of cocoa
and polyphenols during the intervention.

Blood pressure and vascular function will be measured objectively using a
 sphygmomanometer and a Vasera VS-2000 device (Fukuda Denshi), with body
 composition measured by impedance analysis, while the quality of life and cognitive
 performance will be assessed using validated instruments.

- Due to the nature of the intervention, the participants cannot be blinded, although
 the researchers who perform the measurements and the statistical analysis will be
 blinded.

67 INTRODUCTION

Polyphenols are bioactive compounds found in many plants, fruits and vegetables. The beneficial effects on human health associated with the consumption of a diet rich in polyphenols has generated great scientific interest in these substances.[1-3] The action of polyphenols is based on their antioxidant capacity through the uptake of free radicals, the chelation of metals with redox properties and the modulation and inhibition of enzymatic activities.[4]

The most abundant polyphenols in cocoa are flavonoids, which have been linked to a protective effect against cardiovascular disease, decreasing the risk of cardiovascular morbidity and mortality and favouring the prevention of other chronic diseases, such as diabetes mellitus type 2.[1-3, 5-7] The ability to reduce cardiovascular risk could be due to an improvement in the elements that define metabolic syndrome, the improvement of vascular endothelial dysfunction, insulin resistance and the inhibition of platelet activation and aggregation.[8, 9] However, although current evidence suggests that polyphenols produce an improvement in cardiovascular health, this is insufficient to determine the minimum amount of intake necessary to achieve health benefits.[10]

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

85 Cocoa polyphenols and blood pressure:

The effect of consuming polyphenols present in chocolate on the blood pressure statistics of healthy individuals is unclear. Cocoa consumption has been associated with an improvement in endothelial function and a decrease in blood pressure in both healthy subjects and those with risk factors and cardiovascular diseases.[11, 12] Some studies have observed a dose-dependent relationship between cocoa intake and clinical BP, with higher consumption equated to lower blood pressure and better vascular function.[13, 14] Conversely, other research has not obtained significant changes in these parameters related to the supplementation of cocoa or pure polyphenols, such as epicatechin or quercetin.[15, 16]

96 Endothelial dysfunction in postmenopausal women causes changes that favour the 97 development of cardiovascular risk factors and atherosclerosis, which lead to the 98 appearance and maintenance of hypertension.[17, 18] A decrease in blood pressure 99 has been observed in this group after daily consumption of cocoa with a flavonol 100 content of 40.12 mg. Below this level, however, no changes have been observed.[19]

102 Cocoa polyphenols and vascular function:

Among healthy individuals, as well as postmenopausal women, the consumption of polyphenols present in cocoa has been associated with a dose-dependent improvement of vascular function, in particular of arterial stiffness measured by pulse wave speed.[13, 14, 19] One of these studies also suggests that the reduction in arterial stiffness observed in postmenopausal women after consumption of cocoa is independent of the frequency of the intake.[19] However, this relationship is not evident in people with mild hypertension when cardio-ankle vascular index (CAVI) is used as a measure of arterial stiffness.[20]

There is also evidence of the influence of these polyphenols in reducing the augmentation index (Alx). The study by West et al.,[21] involving subjects with excess weight and moderate obesity, concludes that treatment with dark chocolate decreases Alx in women, although it seems that this association might have a greater effect on the elasticity of the large arteries, especially in subjects with obesity and diabetes mellitus type 2.[22]

119 Cocoa polyphenols and cognitive performance:

There is evidence to suggest that chocolate rich in polyphenols is beneficial for cognitive performance and state since it improves mental processing speed and attenuates the increase of mental fatigue among healthy young adults.[23, 24] An improvement in cognitive performance among older age groups after eating chocolate has also been observed, [25] especially in subjects with higher risk of cardiovascular disease.[26] Several studies also show that polyphenol-rich chocolate causes an improvement in executive function, categorical fluency, [27] and working memory, [28, 29] and a slowing of mental fatigue.[30] Also, a higher frequency of chocolate consumption has been associated with improved cognitive function.[29] Furthermore, a positive influence of cocoa polyphenols on physiological processes has been reported, with a neuroprotective effect[31] and improved cognitive performance.[32] In this regard, it has been suggested that the brain-derived neurotrophic factor (BDNF) plays a role in the cognitive enhancement induced by the flavonoides.[33] Favourable effects on cerebrovascular function have also been observed in postmenopausal women after consumption of chocolate with a high concentration of cocoa.[34]

Cocoa polyphenols and quality of life:

The quality of life linked to health is represented by the individual's perception of wellbeing in various aspects of life, including physical and mental aspects. The effect of chocolate and polyphenols on the quality of life has scarcely been studied, with little

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

available evidence and even less of a conclusive nature. In a study conducted among
healthy people, where regular consumption of chocolate was recorded over 1 year, no
evidence was found of a clear association between chocolate intake and the physical
or mental components of quality of life.[35] Nevertheless, it has been observed that the
consumption of dark chocolate might be beneficial for the quality of life of women with
fibromyalgia.[36]

147 Cocoa polyphenols and body composition:

The menopause period leads to various changes in the body composition of women.[37] Regarding the connection between cocoa polyphenols and body composition, results diverge. Some clinical trials involving healthy people and overweight or obese patients have not reported significant differences that link chocolate consumption to anthropometric measures. [16, 20, 21, 38] Other studies indicate that chocolate consumption might have positive effects on body composition in adolescents,[39] patients with diabetes[40] or women with obesity.[41] Two recent systematic reviews also indicate that eating chocolate is associated with reduced body mass index (BMI) and waist circumference, [42, 43] and one of them also concludes that the amount and the length of time during which it is eaten play a key role in these beneficial effects.[43] Conversely, other studies such as that carried out with the cohort of the Atherosclerosis Risk in Communities (ARIC) study have observed a dose-dependent increase in weight after habitual chocolate consumption.[44]

In sum, the polyphenols present in chocolate seem to have a positive effect on BP, vascular function, cognitive performance, and quality of life, especially in populations with increased cardiovascular risk, such as postmenopausal women.[45] However, the conflicting results obtained in different studies suggest that the real contribution of these compounds to health and the underlying mechanisms remain unclear. Moreover,

treatment;

hypocaloric

BMJ Open

most of these studies have used preparations with high concentrations of polyphenols that are usually not present in the normal diet. This study aims to evaluate the effect of adding a daily amount of 10 g of chocolate high in cocoa content (99%) and polyphenols to the normal diet on blood pressure, vascular function, cognitive performance, quality of life, and body composition in postmenopausal women. METHODS AND ANALYSIS Design and setting: This controlled and randomized clinical trial involves two parallel groups. The study will be carried out in the Research Unit of the La Alamedilla Health Centre in Salamanca (Spain), which is part of the Biomedical Research Institute of Salamanca (IBSAL) and the Primary Care Prevention and Health Promotion Research Network (REDIAPP). The recruitment schedule is set to start on June 1, 2018, and the study will run until May 31, 2019. There will be a baseline assessment and two follow-ups, at 3 and 6 months. Study population: Those subjects who meet the selection criteria and sign the informed consent after receiving information about the objectives and implementation of the study will take part.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Inclusion criteria: women between 50- and 64-years-old in postmenopause, defined by

Exclusion criteria: a personal history of cardiovascular disease; personal history of

diabetes mellitus, arterial hypertension or dyslipidemia under pharmacological

demonstrable

neurological

and/or

clinically

and checked against amenorrhea during at least 12 consecutive months.

diets:

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

195	neuropsychological disease; treatment with hormone replacement therapy; intolerance
196	and/or allergy to cocoa or any of the components of the supplement.
197	
198	Participants will be selected using a consecutive sample of women who meet the
199	selection criteria in the GP surgeries of four urban primary care centres in Salamanca,
200	from June 1, 2018.
201	
202	Patient and public involvement:
203	Patients and the public were not involved in the design of this study or outcome
204	measures. We hope that the results of the study will be disseminated through press
205	releases and information-sharing meetings with the study participants.
206	
207	Sample size:
208	The size of the sample has been estimated based on the potential modification of the
209	main variable, systolic blood pressure (SBP). Given alpha and beta risks of 0.05 and
210	0.20 respectively in bilateral contrast and a standard deviation (SD) of 5.8 mmHg, 140
211	participants (70 per group) will be necessary to detect a minimum difference of 2.9
212	mmHg in the SBP between the two groups. A predicted drop-out rate of 10% during
213	follow-up has been taken into account. This estimate has considered the results
214	obtained in a similar study in which a decrease in SBP of 6.5 was observed \pm 5.8
215	mmHg.[14]
216	
217	Randomization:
218	Participants will be assigned to the intervention group (IG) or control group (CG) at
219	random. The allocation sequence will be generated by an independent researcher
220	using the Epidat 4.2 program [46] before the inclusion of the first participant, using
221	masked block randomisation. Patients will receive their randomisation number based

on the order of their baseline evaluation visit and will remain hidden until the

BMJ Open

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41 42	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
55	
54 55	
56	
57	
58	
59	

60

participants are assigned to each group. To ensure that the blinding is maintained,
patients will be given clear instructions not to disclose which treatment they have been
randomised to while being interviewed by the blind assessors. Information on treatment
allocation will be stored in a secure locker in case of emergency unblinding.

227

228 Intervention:

- 229 No type of intervention will be carried out with the CG participants.
- 230

231 IG participants will be given chocolate with 99% cocoa content and asked to eat 10 g 232 daily for 6 months. According to the EFSA (European Food Safety Authority), 10 g of 233 high-flavanol dark chocolate consumed in the context of a balanced diet could help maintain endothelium-dependent vasodilation.[47] Participants will also be given 234 235 instructions on eating and keeping the product, with the recommendations, for 236 example, that the chocolate can be consumed in small pieces leaving them unmated in 237 the mouth, without chewing them. Also, a series of recommendations will be given addressing the organoleptic characteristics of the product, as well as the 238 239 recommendations of trying to consume the product at the same time or refrain from 240 ingesting it dissolved in milk. Also, participants will be given a calendar on which to 241 record the time it was eaten each day. This calendar will be returned to the researchers 242 at each replenishment visit.

243

This amount of chocolate provides the following daily nutritional contribution: 59 Kcal, 0.8 g of carbohydrates, 1.5 g of protein, 5.1 g of fat, of which 3.1 g are saturated fats. The proportion of polyphenols per 10 g is 65.4 mg. The polyphenolic profile of this compound can be seen in Table 1. On each visit, IG participants will receive the amount of chocolate they need until the next replenishment visit. In addition to the baseline visit, there will be five replenishment visits in months 1, 2, 3 (coinciding with the evaluation visit), 4 and 5. The sole purpose of the replenishment visits will be to

Page 12 of 32

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

supply the amount of chocolate needed until the next visit, without any otherintervention being carried out.

254 Participants in both groups will be instructed to continue with the dietary pattern they 255 usually follow, without changing their eating habits during the study period.

257 Procedures:

For each participant a baseline visit and two follow-up visits at 3 and 6 months after the initial one are scheduled (Figure 1). The IG will also make five replenishment visits, in months 1, 2, 3 (coinciding with the first follow-up visit), 4 and 5. In the replenishment visits, participants will be given the amount of chocolate needed until the next visit and will hand in the calendar with the record of the chocolate eaten.

Primary and secondary endpoints:

The primary variable will be the decrease in clinical BP, measured with a digital sphygmomanometer. Secondary variables will include vascular function, quality of life, cognitive performance and body composition.

All variables will be measured at 3 and 6 months after randomization, except for cognitive performance and guality of life, which will be assessed only after 6 months.

272 Blood pressure:

Clinical systolic and diastolic blood pressure will be measured with a validated Omron
M10-IT sphygmomanometer (Omron Healthcare, Kyoto, Japan). Three measurements
will be taken in the dominant arm of the subject in a sitting position after at least 5 min
of rest with an appropriately sized cuff, following the recommendations of the European
Society of Hypertension.[48] The average of the last two measurements will be
recorded.

279	
280	Vascular function:
281	The Vasera VS-2000 device (Fukuda Denshi) will be used to measure the CAVI and
282	the brachial-ankle pulse wave velocity (ba-PWV) at rest. CAVI is a good indicator of
283	arterial stiffness, providing an accurate estimate of the degree of atherosclerosis
284	without depending on blood pressure.[49] CAVI \geq 9 and ba-PWV \geq 18.3 will be
285	considered pathological.[50] Pathological CAVI is representative of subclinical
286	atherosclerosis.[51]
287	
288	Cognitive performance:
289	The instructions are presented visually at the start of the baseline measurement to
290	ensure limiting a learning effect over the subsequent testing periods. Attention and
291	executive functions: Trail Making Test A will be used to measure attention and Trai
292	Making Test B for processing speed and executive functions.[52]
293	
294	Immediate verbal memory will be assessed with the Rey Auditory Verbal Learning
295	Test. The immediate recall of a list of 15 words is measured in three attempts, followed
296	by delayed verbal memory through the free recall of the words learned in the first part
297	of the test after 10 min.[53]
298	
299	Working memory will be assessed with the WAIS Digit Span Backward test.[54]
300	Phonological fluency will be explored by naming as many words as possible starting
301	with different letters of the FAS Questionnaire in the space of 1 min.[55]
302	
303	Categorical fluency measures verbal semantic fluency and will be assessed by naming
304	as many animals as possible in 1 min.[56]
305	
306	Quality of life:
	12
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

The guality of life linked to health will be assessed through the EuroQol 5-D questionnaire (EQ-5D). We will use the adapted Spanish version of this questionnaire, which has been validated in the Spanish population.[57] This questionnaire consists of three elements: the assessment by the individuals of their state of health in level of severity by dimension (mobility, personal care, daily activities, pain/discomfort and anxiety/depression), the assessment of their state of health on an analogue visual scale, and finally an index of social values obtained for each state of health generated by the instrument.

The quality of life will also be studied using the Cervantes Scale.[58] This questionnaire is specifically designed for menopause and postmenopause and has been validated for Spanish women. Its 31 structured items cover the four dimensions of menopause: menopause and health, sexuality, psychic domain and relationships.

321 Body composition:

Body composition will be measured with the Inbody 230 Monitor.[59] This analyzer provides data on fat mass and body fat percentage as principal outcomes and also skeletal muscle mass, total body water, fat-free mass, waist-hip ratio, basal metabolism, and a segmental analysis.

Body weight will be measured twice with an electronic scale (Scale 7830, Soehnle Professional GmbH & Co, Backnang, Germany) after proper calibration (accuracy ± 0.1 kg). Height will be measured by recording the average of two readings rounded to the nearest centimetre using a stadiometer (Seca 222, Medical scale and measurement system, Birmingham, UK). Both measurements will be made with the subject barefoot and wearing light clothing. Body mass index will be calculated by dividing weight (kg) by height squared (m²). Waist circumference will be assessed in accordance with the recommendations of the Spanish Society for the Study of Obesity (SEEDO)[60] and will

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.	Enseignement Superieur (ABES).	BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I
--	--------------------------------	--

335	be measured in duplicate before and after inhalation, using a flexible tape parallel to
336	the floor, at the level of the mid-point between the lowest rib and the iliac crest, with the
337	subject standing up and without clothes.
338	
339	Other variables
340	Clinical and sociodemographic variables
341	At the baseline visit, information on clinical and sociodemographic variables will also be
342	collected via questions about age, marital status, educational level and occupation. The
343	family history of cardiovascular disease and personal history of anxiety and depression,
344	gestational diabetes, hypertension, dyslipidemia and the prescribed pharmacological
345	treatment (antiaggregants, anticoagulants, thyroid hormone treatment, anxiolytics) will
346	also be recorded, as well as the taking of NSAIDs in the last 2 weeks.
347	
348	In subsequent visits, personal histories of cardiovascular disease, diabetes mellitus,
349	arterial hypertension or dyslipidemia in treatment, as well as the prescribed
350	pharmacological treatment (hypolipidemic, antihypertensive, antidiabetic) will also be
351	noted.
352	
353	Evaluation of chocolate consumption and habitual diet
354	Chocolate consumption will be assessed at each evaluation visit by a series of
355	questions about the amount, type and frequency of consumption in the period between
356	visits.
357	
358	Nutritional habits will be assessed by a 24-h log on three non-consecutive days prior to
359	each visit.
360	
361	Evaluation of other lifestyles

The use of tobacco will be assessed with a questionnaire on the personal history and pattern of smoking.

Alcohol use will be recorded with a questionnaire covering the previous 7 days, which will include specific beverages and the amount by volume drunk of each.

Physical activity will be measured using the International Physical Activity Questionnaire (IPAQ) in its short version and validated in Spanish.[61] This questionnaire measures activity over the previous 7 days, classifying the subjects according to three activity levels (low, moderate and high) with respect to three types of activities: walking, moderate-intensity activities and vigorous-intensity activities. The amount of physical exercise will be estimated in METs-minute/week.

375 Evaluation of laboratory variables

At baseline and follow-up visits at 6 months, we will measure plasma fasting glucose values (mg/dL), glycated haemoglobin (%), total cholesterol (mg/dL), total triglycerides (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), creatinine (mg/L), and insulinemia (mg/dL). Creatinine in urine (mg/dL) and microalbuminuria (mg/dL) will also be measured. Insulin resistance will be determined using the HOMA index (Homeostasis Model Assessment Insulin Resistance) estimated using the following equation: Fasting glucose (mmol/l) × insulin (mU/ml)/22.5.

The evaluation visits will be made in the morning between 8:00 and 10:00 a.m. Each participant will be informed prior to the visit to fast for at least 12 h, having avoided during the 24 h prior to visiting the consumption of polyphenol-rich foods, including cocoa, chocolate, apples, and red wine as well as alcoholic drinks or the performance of the programmed physical activity. All evaluation visits, including blood pressure measurements and evaluations of vascular function, will be carried out in a room with

BMJ Open

standardized lighting and temperature, recommending that patients attend the
appointment with a prior rest of at least 8–10 h.

393 Data collection procedure, data management and monitoring

Data collection of the baseline and follow-up evaluation visits at 3 and 6 months will be carried out by a nurse specifically trained to do so. The intervention visit after the baseline evaluation will be carried out by another nurse, different from the one who performs the data collection. Each participant will have a unique identification code within the study. All measurements will be compiled in a data collection notebook and kept in a secure place that will remain closed within the health centre. A database will be created in SPSS to which only the members of the research team and the people related to the statistical analyses will have access. The principal investigator or a person designated for this purpose will perform a weekly process of monitoring the study, taking into account the inclusion of patients, cleaning and debugging of databases, and adaptation of the procedures to the protocol.

406 Blinding strategy:

407 Due to the nature of the intervention itself, the participants and the person responsible 408 for delivering the chocolate to IG participants cannot be blinded. However, the person 409 responsible for carrying out the study measurements at each visit and for the statistical 410 analysis will be blind to the intervention.

412 Statistical analysis:

413 General analysis

Results for the quantitative variables will be expressed by mean ± standard deviation or by frequency distribution in the case of qualitative variables. The normality of the variables will be assessed using the Kolmogorov-Smirnov test. In cases where a normal distribution cannot be assumed, the corresponding nonparametric tests will be

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

418 applied. The association between independent qualitative variables will be analyzed 419 using the Chi-square test or Fisher's exact test. The means between the two groups 420 will be compared using the Student's t-test or the Mann-Whitney U test, and the 421 Pearson or Spearman correlation coefficients will be calculated to analyze the 422 relationship between quantitative variables.

The analysis of the results for the main variable and the secondary variables will be carried out by intention to treat. Also, a secondary analysis will be made, taking into account chocolate intake adherence (< 50% days and > 50% days) and other relevant subgroups in relation to their physical activity or previous chocolate consumption.

428 All analyses will be performed using SPSS version 23.0 (IBM Corporation, Armonk,

429 NY, USA) and an alpha risk of 0.05 will be set as the limit of statistical significance.

431 Analysis of the intervention's effect on primary and secondary outcomes

To analyze the changes at 3 and 6 months from baseline in the primary outcome (blood pressure) and in the secondary outcomes within the same group, the Student's t-test for paired data or the Wilcoxon test will be used. The McNemar test will be applied with quantitative or dichotomous variables.

Effects of the intervention will be analyzed in a comparison of the changes in blood pressure and the secondary variables between the IG and the CG, using ANCOVA and adjusting for possible confounders e.g. smoking status. Effects of the intervention during follow-up will be studied with an analysis of the variance of repeated measures.

442 Analysis by subgroups

The effect of the intervention could be influenced by age, sociocultural level and adherence to the study's chocolate intake. The same analyses described above will be performed for each of the subgroups above.

1		
2 3	446	
4 5	447	Secondary analyses
6 7	448	A multivariate multiple regression analysis will be performed to identify the variables
8 9	449	with the greatest influence on blood pressure changes and the secondary variables
10 11	450	analyzed.
12 13	451	
14 15	452	Methodological limitations:
16 17	453	Due to the nature of the intervention, the participating subjects cannot be blinded.
18 19	454	However, the researcher who analyses the data and the person who makes the
20 21	455	measurements during follow-up visits will be blinded with respect to the group to which
22 23	456	the participants belong. The smoking status in the 12 months prior to the time of
24 25	457	inclusion could influence the outcome measures related to vascular function and blood
26 27	458	pressure; therefore, although these participants will not be excluded, this aspect will be
28 29	459	controlled in the statistical analysis. Assessment of the quality of life and lifestyles will
30 31	460	be carried out through self-reported data; however, previously validated instruments
32 33	461	will be used to obtain these. To make compliance with the intervention in the IG easier,
34 35	462	IG participants will be provided with instructions on eating the chocolate and a calendar
36 37	463	to record each intake.
38 39	464	
40 41	465	ETHICS AND DISSEMINATION
42 43	466	Ethical considerations:
44 45	467	The study was approved by the Clinical Research Ethics Committee of the Salamanca
46 47	468	Health Area ("CREC of Health Area of Salamanca") in February 2018. A SPIRIT
48 49	469	checklist is available for this protocol. The clinical trial has been registered at
50 51	470	ClinicalTrials.gov with the identifier NCT03492983.
52 53	471	
54 55	472	Participants must provide informed consent in accordance with the Declaration of
56 57	473	Helsinki. Subjects will be informed of the objectives of the project and the risks and
58		18

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

benefits of the explorations to be carried out, including sample collection. None of the tests will pose risks that could endanger the lives of participants. Confidentiality of participant data will be guaranteed at all times in accordance with the provisions of the Organic Law on the Protection of Personal Data (15/1999 of December 13, LOPD), and under the conditions established by Law 14/2007 of biomedical research.

Dissemination plan:

The research group plans to achieve rapid and widespread dissemination of results to ensure maximum visibility of this study. To this end, the results of the study will be published in open-access scientific journals with peer review. At least one publication of the main results and others with the secondary results are planned. This will be complemented by the presentation of the results of the study at relevant scientific conferences and seminars of national and international scope. Also, a doctoral thesis based on this project will be prepared. Appropriate dissemination will likewise be carried out through social networks and other media. Moreover, given the involvement of a commercial product, the transfer to clinical practice is expected to be rapid if the results are as expected.

492 DISCUSSION

In recent years, there has been an increase in attention to polyphenols and their beneficial effects on health, with numerous studies being carried out to assess this.[19, 21] Similarly, the therapeutic use of these compounds has been suggested for certain diseases or population groups.[36, 62] The menopause increases the risk of developing cardiovascular disease compared to the previous period. [45] However, we have not found any study that assesses the effect of adding commercially available chocolate high in cocoa content to the usual diet in this population. Similarly, no studies have been found that evaluate the effects on cognitive performance, quality of life and

BMJ Open

body composition of adding commercial chocolate with high cocoa content to the usual diet in postmenopausal women.

This work will provide novel data helpful for the development of strategies in the nutritional education of particularly vulnerable populations, given their high risk of developing cardiovascular disease, including non-pharmacological therapies and strategies that employ lifestyle modification. This intervention might also have implications for the preparation of recommendations in clinical practice guidelines and quality improvement programs aimed at the care of postmenopausal women.

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

ur (ABES) . data mining, Al training, and similar technologies.

1	
2	
3	
4	
5 6	
7	
8	
9	
10	
11 12	
13	
14	
12 13 14 15 16	
16 17	
18	
18 19 20	
20	
21 22	
23	
24	
25	
26	
27 27 28	
29	
30	
31	
32 33	
34	
35	
35 36 37	
37 38	
39	
40	
41 42	
42 43	
44	
45	
46 47	
47 48	
49	
50	
51 52	
52 53	
54	
55	
56	
57 58	
59	
~~	

510 **REFERENCES**

511	1. Grassi D, Desideri G, Ferri C. Flavonoids: antioxidants against atherosclerosis. Nutrients
512	2010;2(8):889-902. doi: 10.3390/nu2080889 [published Online First: 2010/08/01]
513	2. Grassi D, Desideri G, Croce G, et al. Flavonoids, vascular function and cardiovascular
514	protection. Curr Pharm Des 2009;15(10):1072-84. [published Online First: 2009/04/10]
515	3. Visioli F, Bernaert H, Corti R, et al. Chocolate, lifestyle, and health. Crit Rev Food Sci Nutr
516	2009;49(4):299-312. doi: 10.1080/10408390802066805 [published Online First:
517	2009/02/24]
518	4. Cos P, De Bruyne T, Hermans N, et al. Proanthocyanidins in health care: current and new
519	trends. Curr Med Chem 2004;11(10):1345-59. [published Online First: 2004/05/12]
520	5. Grassi D, Desideri G, Ferri C. Blood pressure and cardiovascular risk: what about cocoa and
521	chocolate? Arch Biochem Biophys 2010;501(1):112-5. doi: 10.1016/j.abb.2010.05.020
522	[published Online First: 2010/05/25]
523	6. Mink PJ, Scrafford CG, Barraj LM, et al. Flavonoid intake and cardiovascular disease
524	mortality: a prospective study in postmenopausal women. Am J Clin Nutr
525	2007;85(3):895-909. doi: 10.1093/ajcn/85.3.895 [published Online First: 2007/03/09]
526	7. Ramos S, Martin MA, Goya L. Effects of Cocoa Antioxidants in Type 2 Diabetes Mellitus.
527	Antioxidants (Basel) 2017;6(4) doi: 10.3390/antiox6040084 [published Online First:
528	2017/11/01]
529	8. Osakabe N. Flavan 3-ols improve metabolic syndrome risk factors: evidence and
530	mechanisms. J Clin Biochem Nutr 2013;52(3):186-92. doi: 10.3164/jcbn.12-130
530	[published Online First: 2013/05/25]
531	9. Engler MB, Engler MM, Chen CY, et al. Flavonoid-rich dark chocolate improves endothelial
533	function and increases plasma epicatechin concentrations in healthy adults. J Am Coll
534	Nutr 2004;23(3):197-204. [published Online First: 2004/06/11]
535	10. Ottaviani JI, Heiss C, Spencer JPE, et al. Recommending flavanols and procyanidins for
536	cardiovascular health: Revisited. <i>Mol Aspects Med</i> 2018;61:63-75. doi:
537	10.1016/j.mam.2018.02.001 [published Online First: 2018/02/11]
538	11. Ludovici V, Barthelmes J, Nagele MP, et al. Cocoa, Blood Pressure, and Vascular Function.
539	Front Nutr 2017;4:36. doi: 10.3389/fnut.2017.00036 [published Online First:
540	2017/08/22]
541	12. Ried K, Fakler P, Stocks NP. Effect of cocoa on blood pressure. <i>Cochrane Database Syst Rev</i>
542	2017;4:CD008893. doi: 10.1002/14651858.CD008893.pub3 [published Online First:
543	2017/04/26]
544	13. Heiss C, Sansone R, Karimi H, et al. Impact of cocoa flavanol intake on age-dependent
545	vascular stiffness in healthy men: a randomized, controlled, double-masked trial. Age
546	(Dordr) 2015;37(3):9794. doi: 10.1007/s11357-015-9794-9 [published Online First:
547	2015/05/28]
548	14. Grassi D, Desideri G, Necozione S, et al. Cocoa consumption dose-dependently improves
549	flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy
550	individuals. J Hypertens 2015;33(2):294-303. doi: 10.1097/hjh.000000000000412
551	[published Online First: 2014/11/08]
552	15. Crews WD, Jr., Harrison DW, Wright JW. A double-blind, placebo-controlled, randomized
553	trial of the effects of dark chocolate and cocoa on variables associated with
554	neuropsychological functioning and cardiovascular health: clinical findings from a
555	sample of healthy, cognitively intact older adults. Am J Clin Nutr 2008;87(4):872-80.
556	[published Online First: 2008/04/11]
557	16. Dower JI, Geleijnse JM, Gijsbers L, et al. Effects of the pure flavonoids epicatechin and
558	quercetin on vascular function and cardiometabolic health: a randomized, double-
559	blind, placebo-controlled, crossover trial. Am J Clin Nutr 2015;101(5):914-21. doi:
560	10.3945/ajcn.114.098590 [published Online First: 2015/05/03]
	21
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
3	561	17. Modena MG. Hypertension in postmenopausal women: how to approach hypertension in
4	562	menopause. High Blood Press Cardiovasc Prev 2014;21(3):201-4. doi: 10.1007/s40292-
5	563	014-0057-0 [published Online First: 2014/05/24]
6	564	18. Zilberman JM, Cerezo GH, Del Sueldo M, et al. Association Between Hypertension,
7	565	Menopause, and Cognition in Women. J Clin Hypertens (Greenwich) 2015;17(12):970-
8	566	6. doi: 10.1111/jch.12643 [published Online First: 2015/08/08]
9	567	19. Okamoto T, Kobayashi R, Natsume M, et al. Habitual cocoa intake reduces arterial stiffness
10	568	in postmenopausal women regardless of intake frequency: a randomized parallel-
11	569	group study. Clin Interv Aging 2016;11:1645-52. doi: 10.2147/cia.s118152 [published
12	570	Online First: 2016/11/25]
13	571	20. Koli R, Kohler K, Tonteri E, et al. Dark chocolate and reduced snack consumption in mildly
14	572	hypertensive adults: an intervention study. Nutr J 2015;14:84. doi: 10.1186/s12937-
15	573	015-0075-3 [published Online First: 2015/08/25]
16	574	21. West SG, McIntyre MD, Piotrowski MJ, et al. Effects of dark chocolate and cocoa
17	575	consumption on endothelial function and arterial stiffness in overweight adults. Br J
18	576	Nutr 2014;111(4):653-61. doi: 10.1017/s0007114513002912 [published Online First:
19	570	2013/11/28]
20	578	22. Basu A, Betts NM, Leyva MJ, et al. Acute Cocoa Supplementation Increases Postprandial
21	578	HDL Cholesterol and Insulin in Obese Adults with Type 2 Diabetes after Consumption
22	580	of a High-Fat Breakfast. J Nutr 2015;145(10):2325-32. doi: 10.3945/jn.115.215772
23	580	[published Online First: 2015/09/05]
24	582	23. Scholey AB, French SJ, Morris PJ, et al. Consumption of cocoa flavanols results in acute
25		improvements in mood and cognitive performance during sustained mental effort. J
26	583	
27	584	Psychopharmacol 2010;24(10):1505-14. doi: 10.1177/0269881109106923 [published
28 29	585	Online First: 2009/11/28]
29 30	586	24. Field DT, Williams CM, Butler LT. Consumption of cocoa flavanols results in an acute
30	587	improvement in visual and cognitive functions. <i>Physiol Behav</i> 2011;103(3-4):255-60.
32	588	doi: 10.1016/j.physbeh.2011.02.013 [published Online First: 2011/02/18]
33	589	25. Sorond FA, Hurwitz S, Salat DH, et al. Neurovascular coupling, cerebral white matter
34	590	integrity, and response to cocoa in older people. <i>Neurology</i> 2013;81(10):904-9. doi:
35	591	10.1212/WNL.0b013e3182a351aa [published Online First: 2013/08/09]
36	592	26. Socci V, Tempesta D, Desideri G, et al. Enhancing Human Cognition with Cocoa Flavonoids.
37	593	Front Nutr 2017;4:19. doi: 10.3389/fnut.2017.00019 [published Online First:
38	594	2017/06/01]
39	595	27. Mastroiacovo D, Kwik-Uribe C, Grassi D, et al. Cocoa flavanol consumption improves
40	596	cognitive function, blood pressure control, and metabolic profile in elderly subjects:
41	597	the Cocoa, Cognition, and Aging (CoCoA) Studya randomized controlled trial. Am J
42	598	Clin Nutr 2015;101(3):538-48. doi: 10.3945/ajcn.114.092189 [published Online First:
43	599	2015/03/04]
44	600	28. Grassi D, Socci V, Tempesta D, et al. Flavanol-rich chocolate acutely improves arterial
45	601	function and working memory performance counteracting the effects of sleep
46	602	deprivation in healthy individuals. <i>J Hypertens</i> 2016;34(7):1298-308. doi:
47	603	10.1097/hjh.0000000000000926 [published Online First: 2016/04/19]
48	604	29. Crichton GE, Elias MF, Alkerwi A. Chocolate intake is associated with better cognitive
49	605	function: The Maine-Syracuse Longitudinal Study. Appetite 2016;100:126-32. doi:
50	606	10.1016/j.appet.2016.02.010 [published Online First: 2016/02/14]
51	607	30. Massee LA, Ried K, Pase M, et al. The acute and sub-chronic effects of cocoa flavanols on
52	608	mood, cognitive and cardiovascular health in young healthy adults: a randomized,
53	609	controlled trial. Front Pharmacol 2015;6:93. doi: 10.3389/fphar.2015.00093 [published
54	610	Online First: 2015/06/05]
55		
56		
57		
58		22

24	631 632	37. Dmitruk A, Czeczelewski J, Czeczelewska E, et al. Body composition and fatty tissue
25	632	distribution in women with various menstrual status. Rocz Panstw Zakl Hig
26	633	2018;69(1):95-101. [published Online First: 2018/03/10]
27	634	38. Davison K, Coates AM, Buckley JD, et al. Effect of cocoa flavanols and exercise on
28 29	635 636	cardiometabolic risk factors in overweight and obese subjects. Int J Obes (Lond)
30	637	2008;32(8):1289-96. doi: 10.1038/ijo.2008.66 [published Online First: 2008/05/28] 39. Cuenca-Garcia M, Ruiz JR, Ortega FB, et al. Association between chocolate consumption
31	638	and fatness in European adolescents. <i>Nutrition</i> 2014;30(2):236-9. doi:
32	639	10.1016/j.nut.2013.07.011 [published Online First: 2013/10/22]
33	640	40. Ayoobi N, Jafarirad S, Haghighizadeh MH, et al. Protective Effect of Dark Chocolate on
34	641	Cardiovascular Disease Factors and Body Composition in Type 2 Diabetes: A Parallel,
35 36	642	Randomized, Clinical Trial. Iran Red Crescent Med J 2017;19(8):e21644. doi:
37	643	10.5812/ircmj.21644 [published Online First: 2017-08-01]
38	644 645	41. Di Renzo L, Rizzo M, Sarlo F, et al. Effects of dark chocolate in a population of normal weight obese women: a pilot study. <i>Eur Rev Med Pharmacol Sci</i> 2013;17(16):2257-66.
39	645 646	[published Online First: 2013/07/31]
	040	
40	647	42. González-Sarrías A. Combet F. Pinto P. et al. A Systematic Review and Meta-Analysis of the
41	647 648	42. González-Sarrías A, Combet E, Pinto P, et al. A Systematic Review and Meta-Analysis of the Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition
41 42	647 648 649	42. González-Sarrías A, Combet E, Pinto P, et al. A Systematic Review and Meta-Analysis of the Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy.
41	648 649 650	Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746.
41 42 43	648 649 650 651	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate
41 42 43 44 45 46	648 649 650 651 652	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist
41 42 43 44 45 46 47	648 649 650 651 652 653	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized
41 42 43 44 45 46 47 48	648 649 650 651 652 653 654	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820
41 42 43 44 45 46 47 48 49	648 649 650 651 652 653 654 655	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20]
41 42 43 44 45 46 47 48	648 649 650 651 652 653 654 655 656	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a
41 42 43 44 45 46 47 48 49 50	648 649 650 651 652 653 654 655 656 657	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a dose-response manner. <i>PLoS One</i> 2013;8(8):e70271. doi:
41 42 43 44 45 46 47 48 49 50 51 52 53	648 649 650 651 652 653 654 655 656 657 658	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a dose-response manner. <i>PLoS One</i> 2013;8(8):e70271. doi: 10.1371/journal.pone.0070271 [published Online First: 2013/08/21]
41 42 43 44 45 46 47 48 49 50 51 52 53 54	648 649 650 651 652 653 654 655 656 657	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a dose-response manner. <i>PLoS One</i> 2013;8(8):e70271. doi:
41 42 43 44 45 46 47 48 49 50 51 52 53 53 54 55	648 649 650 651 652 653 654 655 656 657 658 659	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a dose-response manner. <i>PLoS One</i> 2013;8(8):e70271. doi: 10.1371/journal.pone.0070271 [published Online First: 2013/08/21] 45. Agrinier N, Cournot M, Dallongeville J, et al. Menopause and modifiable coronary heart
41 42 43 44 45 46 47 48 49 50 51 51 52 53 54 55 56	648 649 650 651 652 653 654 655 656 657 658 659 660	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a dose-response manner. <i>PLoS One</i> 2013;8(8):e70271. doi: 10.1371/journal.pone.0070271 [published Online First: 2013/08/21] 45. Agrinier N, Cournot M, Dallongeville J, et al. Menopause and modifiable coronary heart disease risk factors: a population based study. <i>Maturitas</i> 2010;65(3):237-43. doi:
41 42 43 44 45 46 47 48 49 50 51 51 52 53 54 55 56 57	648 649 650 651 652 653 654 655 656 657 658 659 660	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a dose-response manner. <i>PLoS One</i> 2013;8(8):e70271. doi: 10.1371/journal.pone.0070271 [published Online First: 2013/08/21] 45. Agrinier N, Cournot M, Dallongeville J, et al. Menopause and modifiable coronary heart disease risk factors: a population based study. <i>Maturitas</i> 2010;65(3):237-43. doi: 10.1016/j.maturitas.2009.11.023 [published Online First: 2009/12/25]
41 42 43 44 45 46 47 48 49 50 51 51 52 53 54 55 56	648 649 650 651 652 653 654 655 656 657 658 659 660	 Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. <i>Nutrients</i> 2017;9(7):746. 43. Kord-Varkaneh H, Ghaedi E, Nazary-Vanani A, et al. Does cocoa/dark chocolate supplementation have favorable effect on body weight, body mass index and waist circumference? A systematic review, meta-analysis and dose-response of randomized clinical trials. <i>Crit Rev Food Sci Nutr</i> 2018:0. doi: 10.1080/10408398.2018.1451820 [published Online First: 2018/03/20] 44. Greenberg JA, Buijsse B. Habitual chocolate consumption may increase body weight in a dose-response manner. <i>PLoS One</i> 2013;8(8):e70271. doi: 10.1371/journal.pone.0070271 [published Online First: 2013/08/21] 45. Agrinier N, Cournot M, Dallongeville J, et al. Menopause and modifiable coronary heart disease risk factors: a population based study. <i>Maturitas</i> 2010;65(3):237-43. doi:

1		
2	662	4C. Consollaría da Canidada Vunto da Calicia, Casin, Dan American Organization health (DAUO
3	662 663	46. Consellería de Sanidade Xunta de Galicia. Spain; Pan American Organization health (PAHO- WHO); CES University C. Epidat: program for epidemiological data analysis. Versior
4 r	664	4.2Julio 2016.
5 6	665	47. Scientific Opinion on the substantiation of a health claim related to cocoa flavanols and
7	666	maintenance of normal endothelium-dependent vasodilation pursuant to Article 13(5
8	667	of Regulation (EC) No 1924/2006. EFSA Journal 2012;10(7):2809. doi
9	668	doi:10.2903/j.efsa.2012.2809
10	669	48. Allen JK, Stephens J, Dennison Himmelfarb CR, et al. Randomized controlled pilot study
11	670	testing use of smartphone technology for obesity treatment. J Obes
12	671	2013;2013:151597. doi: 10.1155/2013/151597 [published Online First: 2014/01/07]
13	672	49. Shirai K, Hiruta N, Song M, et al. Cardio-ankle vascular index (CAVI) as a novel indicator o
14	673	arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb
15	674	2011;18(11):924-38. [published Online First: 2011/06/02]
16	675	50. Ohkuma T, Tomiyama H, Ninomiya T, et al. Proposed Cutoff Value of Brachial-Ankle Pulse
17	676	Wave Velocity for the Management of Hypertension. <i>Circ J</i> 2017;81(10):1540-42. doi
18	677	10.1253/circj.CJ-17-0636 [published Online First: 2017/08/25]
19	678	51. Korkmaz L, Erkan H, Korkmaz AA, et al. Relationship of aortic knob width with cardio-ankle
20	679	vascular stiffness index and its value in diagnosis of subclinical atherosclerosis ir
21 22	680	hypertensive patients: a study on diagnostic accuracy. Anadolu Kardiyol Derg
22	681	2012;12(2):102-6. doi: 10.5152/akd.2012.034 [published Online First: 2012/01/28]
23 24	682	52. Reitan RM. Trail Making Test. Tucson: Reitan Neuropsychology Laboratory 1992.
25	683	53. Rey A. L'examen clinique en psychologie. Paris: Presses universitaires de France 1964.
26	684	54. Wechsler D. WMS-R Wechsler memory scale. San Antonio, Texas: The Psychologica
27	685	Corporation 1987.
28	686	55. Valencia NJ, Laserna, J. A., Pérez-García, M., Orozco, C., Miñán, M., Garrido, C., Morente, G
29	687	Influencia de la escolaridad y el sexo sobre la ejecución en el FAS, nombrar animales y
30	688	nombrar frutas. <i>Psicología Conductual</i> 2000;8(2):283-95.
31	689	
31 32		56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986.
31 32 33	689	56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQoI 5-D in the Catalan genera
31 32 33 34	689 690	56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986.
31 32 33 34 35	689 690 691	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22
31 32 33 34 35 36	689 690 691 692	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04]
31 32 33 34 35 36 37	689 690 691 692 693	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish
31 32 33 34 35 36 37 38	689 690 691 692 693 694	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the
31 32 33 34 35 36 37 38 39	689 690 691 692 693 694 695	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First
31 32 33 34 35 36 37 38 39 40	689 690 691 692 693 694 695 696	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12]
31 32 33 34 35 36 37 38 39 40 41	689 690 691 692 693 694 695 696 697	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable
31 32 33 34 35 36 37 38 39 40	689 690 691 692 693 694 695 696 697 698	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02]
31 32 33 34 35 36 37 38 39 40 41 42	689 690 691 692 693 694 695 696 697 698 699	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation of the evaluation of the section of the section of the construct of the evaluation of the section of the se
31 32 33 34 35 36 37 38 39 40 41 42 43	689 690 691 692 693 694 695 696 697 698 699 700 701 702	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria]
31 32 33 34 35 36 37 38 39 40 41 42 43 44	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation of the evaluation of the section of the section of the construct of the evaluation of the section of the se
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 703 704	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15]
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity]
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi:
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30]
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. <i>Oxid Med Cell Longen</i>
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First: 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. <i>Oxid Med Cell Longen</i>
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First: 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. <i>Oxid Med Cell Longen</i>
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First: 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. <i>Oxid Med Cell Longen</i>
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. <i>Oxid Med Cell Longer</i> 2016;2016:5137431. doi: 10.1155/2016/5137431 [published Online First: 2016/10/11]
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711	 56. Goodglass H KE. Evaluación de la Afasia y de Trastornos Relacionados1986. 57. Badia X, Schiaffino A, Alonso J, et al. Using the EuroQol 5-D in the Catalan genera population: feasibility and construct validity. <i>Qual Life Res</i> 1998;7(4):311-22 [published Online First: 1998/06/04] 58. Palacios S, Ferrer-Barriendos J, Parrilla JJ, et al. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. <i>Med Clin (Barc)</i> 2004;122(6):205-11. [published Online First: 2004/03/12] 59. Karelis AD, Chamberland G, Aubertin-Leheudre M, et al. Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. <i>Appl Physio Nutr Metab</i> 2013;38(1):27-32. doi: 10.1139/apnm-2012-0129 [published Online First 2013/02/02] 60. Salas-Salvado J, Rubio MA, Barbany M, et al. [SEEDO 2007 Consensus for the evaluation or overweight and obesity and the establishment of therapeutic intervention criteria] <i>Med Clin (Barc)</i> 2007;128(5):184-96; quiz 1 p following 200. [published Online First 2007/02/15] 61. Roman Vinas B, Ribas Barba L, Ngo J, et al. [Validity of the international physical activity questionnaire in the Catalan population (Spain)]. <i>Gac Sanit</i> 2013;27(3):254-7. doi 10.1016/j.gaceta.2012.05.013 [published Online First: 2012/10/30] 62. Islam MA, Alam F, Solayman M, et al. Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative Diseases. <i>Oxid Med Cell Longen</i>

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

data mining, Al training, and similar technologies

Protected by copyright, including for uses related to text and

713 AUTHORS' CONTRIBUTIONS:

JIR, JAM, LGO and IGY contributed to the conception and design of the study. IGY, JIR and JAM prepared the manuscript of the study protocol. JIR, JAM, LGO, RAD, SMS, JGS, SMG, ERS, MGM and IGY contributed to the development of the study protocol. JIR, JAM, LGO, RAD, SMS, JGS, SMG, ERS, MGM and IGY provided assistance with statistical methodology and knowledge. JIR, JAM, LGO, RAD, SMS, JGS, SMG, ERS, MGM and IGY provided a critical review of the manuscript.

BMJ Open

- All authors have read and accepted the final version of the protocol.

722 FUNDING STATEMENT:

This study was supported in part by grants funded by la Gerencia Regional de Castilla y León (GRS 1583/B/17). "Lindt & Sprüngli will provide the necessary chocolate for the implementation of the study. This company will not play any role in the design of the study, data analysis, reporting of results or the decision to present the manuscript for publication".

729 COMPETING INTERESTS STATEMENT:

The authors declare that they have no conflicts of interest.

732 ACKNOWLEDGMENTS:

733 The authors are grateful to all the professionals involved in the ECCAMP study:

José I Recio-Rodríguez, José A Maderuelo-Fernández, Luis García-Ortiz, Manuel A
Gómez-Marcos, Irene A García-Yu, Rosario Alonso-Domínguez, Sara Mora-Simón,
Natalia Sánchez-Aguadero, Jesús González-Sánchez, Cristina Agudo-Conde, Cristina
Lugones-Sánchez, Benigna Sánchez-Salgado, Carmen Castaño-Sánchez, Emiliano
Rodríguez-Sánchez, Susana González-Manzano, Olaya Tamayo-Morales, and Susana
González-Sánchez.

741 FIGURE LEGEND:


- Figure 1. Study flow chart.
- Table 1. Polyphenol composition of 99% cocoa chocolate

Table 1. Polyphenols composition of 99% cocoa chocolate.



Page 28 of 32

BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.





STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormation		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Pag 1, line 1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Pag 2, line 48
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	Pag 25, line 723
Roles and	5a	Names, affiliations, and roles of protocol contributors	Pag 25, line 714
responsibilities	5b	Name and contact information for the trial sponsor	Pag 25, line 723
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	Pag 25, line 725
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Pag 25, line 714
		to in the company of the company o	

BMJ Open: first published as 10.1136/pmjopen-2018. Downloaded from http://pmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

2						
3 4	Introduction					
5 6 7	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Pag 7, line 162		
8		6b	Explanation for choice of comparators	Pag 7, line 162		
9 10	Objectives	7	Specific objectives or hypotheses	Pag 8, line 170		
11 12 13 14	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Pag 8, line 177		
15 16	Methods: Participa	nts, inte	erventions, and outcomes			
17 18 19	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Pag 9, line 199		
20 21 22	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Pag 8, line 190		
23 24 25	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Pag 10, line 2229		
26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	NA		
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	Pag 10, line 240		
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	Pag 10, line 234		
34 35 36 37 38 39 40 41	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Pag 11, line 265		
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1		
42 43				2	2	
44 45			Protected by copyright, instructed selected selected so text and identify mitting, Ab training, and similar technologies			
45 46 47	I ab aupidargoling and activity in the start of the start					

Page	31	of	32
------	----	----	----

2 3 4	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Pag 9, line 208			
5 6 7 8 9	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	Pag 9, line 198			
	Methods: Assignment of interventions (for controlled trials)						
10	Allocation:						
11 12 13 14 15 16	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Pag 9, line 219			
17 18 19 20	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Pag 10, line 225			
21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Pag 9, line 219			
24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Pag 16, line 407			
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Pag 16, line 407			
30 31 32	Methods: Data collection, management, and analysis						
32 33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Pag 11, line 273			
38 39 40		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	NA			
41 42 43					3		
43 44 45 46 47	Protected by copyright, instruction of the monoder of the monodero						

2 3 4 5	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Pag 16, line 401		
6 7 8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Pag 17, line 424		
9 10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Pag 18, line 443		
11 12 13 14		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	Pag 17, line 426		
15 16	Methods: Monitorin	g				
17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	NA		
22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA		
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	NA		
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA		
31 32	Ethics and dissemin	nation				
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Pag 18, line 467		
37 38 39 40	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	NA		
41 42 43					4	
44			a Salau way			
45 46 47 I	BMJ Open: first published as 10.1136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright,אופעוולאיאנאנאנאנאנאנאנאנאנאנאנאנאנאנאנאנאנאנא					

1							
2 3 4 5 6 7 8 9 10 11 12 13	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Pag 18, line 472			
		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA			
	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Pag 19, line 475			
	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Pag 25, line 730			
14 15 16	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Pag 16, line 400			
17 18 19	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA			
20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Pag 19, line 481			
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers	Pag 19, line 481			
26 27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Pag 19, line 481			
28 29	Appendices						
30 31 32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA			
33 34 35 36 37 38 39 40 41 42 43	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA			
	*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons " <u>Attribution-NonCommercial-NoDerivs 3.0 Unported</u> " license.						
				5			
44			e Recence on the Representation on the Atta // April preparity care/site/about/angidalines. visited. (
45 46	BBAJ Open: first published as 10.136/bmjopen-2018-024095 on 14 December 2018. Downloaded from http://mjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de I Enseignement Superieur (BEES) Protected by copyright, insluight الموابطة عوابلوه عوابلوه عوابلوه علم بلوبليا المالية بلوليا المالية. في المالية بلوليا المالية المالية المالية بلوليا المالي المالية بلوليا المالية المالي						
47 '	-b and developed by the 3000 S and a second behavior and second by a 30000-9100-academy as hedsilding tarify and MA						